

---

# KWAZULU-NATAL POPULATION-BASED CANCER REGISTRY 2024 REPORT

---

Durban, South Africa, March 2026



**NATIONAL CANCER REGISTRY**

Division of the National Health Laboratory Service



**health**

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

**Copyright © 2026**

**Citation:**

**Cancer and Infectious Disease Research Unit. KwaZulu-Natal Population-Based Cancer  
Registry 2024 Report. [www.cideru.ukzn.ac.za](http://www.cideru.ukzn.ac.za)**

**Compiled by:**

Ms. Noluthando Mbeje (Cancer Registrar, CIDERU)

Ms. Babongile Ndlovu (Epidemiologist, NCR)

Dr. Nkosana Jafta (Senior lecturer, CIDERU)

Prof Themba G. Ginindza (Senior Epidemiologist, Director: CIDERU)

Dr Judith Mwansa-Kambafwile (Senior Epidemiologist, NCR)

Dr Mazvita Muchengeti (Head of Department, NCR)

Dr Siyabonga Dlamini (Senior lecturer, CIDERU)

Prof Khumbulani Hlongwana (Senior lecturer, CIDERU)

**KwaZulu-Natal Population-Based Cancer Registry Cancer Information Officers:**

Noxolo Mjwara (Cancer Information Officer, CIDERU)

Nelisiwe Mncwabe (Cancer Information Officer, CIDERU)

Sisanda Ntshela (Cancer Information Officer, CIDERU)

Nonkululeko Sibiyi (Cancer Information Officer, CIDERU)

Sivuyisiwe Solala (Cancer Information Officer, CIDERU)

**Contact Details****KwaZulu-Natal Population-Based Cancer Registry**

Cancer and Infectious Diseases Epidemiology Unit

Discipline of Public Health Medicine, University of KwaZulu-Natal

2nd Floor George Campbell Building (North Entrance)

Howard College, Durban

South Africa

Tel: +27 31 260 4649

Website: [www.cideru.ukzn.ac.za](http://www.cideru.ukzn.ac.za)

## **DISCLAIMER**

This report includes all reported cancer cases for eThekweni residents diagnosed from 1<sup>st</sup> January 2024 to 31<sup>st</sup> December 2024 as recorded in the KwaZulu-Natal Population-Based Cancer Registry (KZN-PBCR). The information reflects the data at the time of closing the 2024 database for cleaning and analysis on 13 February 2026. The KZN-PBCR continues to receive and collect additional data; therefore, the data may be updated as and when necessary. Special requests for data should be directed to the Cancer Registrar, Ms Noluthando Mbeje, [mlccp@ukzn.ac.za](mailto:mlccp@ukzn.ac.za).

# TABLE OF CONTENTS

<b>DISCLAIMER.....</b>	<b>1</b>
LIST OF TABLES .....	3
LIST OF FIGURES .....	3
FOREWORD .....	5
INTRODUCTION .....	1
METHODS .....	3
<b>Data sources.....</b>	<b>3</b>
<b>Data Collection and Processes .....</b>	<b>5</b>
<b>Confidentiality.....</b>	<b>7</b>
<b>Statistical Analysis .....</b>	<b>8</b>
RESULTS .....	9
<b>Overall cancer incidence .....</b>	<b>9</b>
<b>Childhood cancer incidence .....</b>	<b>19</b>
<b>Data Quality Indicators.....</b>	<b>20</b>
DISCUSSION.....	22
CONCLUSION.....	24
ACKNOWLEDGEMENTS.....	25
REFERENCES .....	26
APPENDICES .....	28

## LIST OF TABLES

Table 1: Summary statistics for all cancers in males, KZN-PBCR 2024 .....	100
Table 2: Summary statistics for all cancers in females, KZN -BCR 2024.....	12
Table 3: Childhood cancers, KZN-PBCR 2024.....	19
Table 4: Percentage of cases morphologically verified (mv), diagnosed clinically or diagnosed by death certificate only (dco), KZN-PBCR 2024.....	20

## LIST OF FIGURES

FIGURE 1: KWAZULU-NATAL POPULATION-BASED CANCER REGISTRY DATA SOURCES MAP, 2024.....	5
FIGURE 2: KWAZULU-NATAL POPULATION-BASED CANCER REGISTRY DATA FLOW DIAGRAM, 2024.....	7
FIGURE 3: PERCENTAGE OF CANCER CASES BY SEX AND POPULATION GROUP, KZN-PBCR 2024. ....	9
FIGURE 4: FREQUENCY OF MOST COMMON CANCERS IN MALES, KZN-PBCR 2024 .....	14
FIGURE 5: AGE STANDARDISED INCIDENCE RATES FOR THE MOST COMMON CANCERS IN MALES, KZN-PBCR 2024 .....	14
FIGURE 6: FREQUENCY OF MOST COMMON CANCERS IN FEMALES, KZN-PBCR 2024.....	15
FIGURE 7: AGE-STANDARDISED INCIDENCE RATES FOR COMMON CANCERS IN FEMALES, KZN-PBCR 2024 .....	15
FIGURE 8: ASR FOR TOP 5 CANCERS IN MALES BY POPULATION GROUP, KZN-PBCR 2024.....	16
FIGURE 9: ASR FOR TOP 5 CANCERS IN FEMALES BY POPULATION GROUP, KZN-PBCR 2024.....	16
FIGURE 10: ASRS FOR MOST COMMON CANCERS IN MEN, 2023-2024.....	17
FIGURE 11: ASRS FOR MOST COMMON CANCERS IN WOMEN, 2023-2024.....	18
FIGURE 12: NUMBER OF CANCER CASES REPORTED BY YEAR AND SEX, KZN-PBCR 2023-2024.....	18
FIGURE 13: PERCENTAGE OF CANCER CASES BY SEX AND POPULATION GROUP, ZULULAND DISTRICT 2024.....	30
FIGURE 14: FREQUENCY OF MOST COMMON CANCERS IN MALES, ZULULAND DISTRICT 2024.....	31
FIGURE 15: FREQUENCY OF MOST COMMON CANCERS IN FEMALES, ZULULAND DISTRICT 2024.....	31

## ACRONYMS AND ABBREVIATIONS

AFCRN:	African Cancer Registry Network
ASR:	Age-Standardised Incidence Rate
BCC:	Basal Cell Carcinoma
BMSF:	Bristol Myers Squibb Foundation
CIDERU:	Cancer & Infectious Diseases Epidemiology Research Unit
CNS:	Central Nervous System
CCPAC:	Cervical Cancer Prevention, Access and Control
CIOs:	Cancer Information Officers
DoH:	Department of Health, South Africa
DHA:	Department of Home Affairs, South Africa
IACR:	International Association of Cancer Registries
IARC:	International Agency for Research on Cancer
ICCC:	International Classification of Childhood Cancer
ICDO-3:	International Classification of Diseases for Oncology, Third Edition
ICON:	Independent Clinical Oncology Network
HBCR:	Hospital-Based Cancer Registry
KZN-PBCR:	KwaZulu-Natal Population-Based Cancer Registry
KZN:	KwaZulu-Natal
LMIC:	Low- or Middle-Income Country
MoU:	Memorandum of Understanding
NCDs:	Non-Communicable Disease
NCR:	National Cancer Registry, South Africa
NHLS:	National Health Laboratory Services
PBCR:	Population-Based Cancer Registry
POPI Act:	Protection of Personal Information Act, South Africa
PSU:	Primary Site Unknown
SA:	South Africa
SAOC:	South African Oncology Consortium
STATSSA:	Statistics South Africa
UICC:	Union for International Cancer Control
WHO:	World Health Organization
WSP:	World Standard Population

## FOREWORD

It gives me great pleasure to present the 2024 Annual Report of the KwaZulu-Natal Population-Based Cancer Registry (KZN-PBCR).

This cancer incidence report marks the second annual cancer incidence report produced by the KZN-PBCR, South Africa's second population-based cancer registry, uniquely positioned to capture data across both rural and urban populations within the province. As such, it represents a critical step forward in strengthening comprehensive cancer surveillance in the country.

The successful production of this report has been made possible through the CIDERU-BMSF-funded Multinational Lung Cancer Control Program (MLCCP), with invaluable support from the National Health Laboratory Service (NHLS), the National Cancer Registry (NCR), the KwaZulu-Natal Department of Health, and private sector stakeholders working within the oncology landscape.

This report provides essential insights into the burden of cancer in KwaZulu-Natal, including patterns of diagnosis and management. These data are vital for informing evidence-based planning, resource allocation, and the development of targeted cancer control strategies at both provincial and national levels.

The vision of the KZN-PBCR is to achieve internationally recognised standards in cancer surveillance, enabling the routine reporting of high-quality incidence data from KwaZulu-Natal to global bodies such as the International Agency for Research on Cancer (IARC). Ultimately, this will ensure that local data meaningfully contributes to global cancer intelligence while directly informing policy and improving health outcomes within South Africa.

I would like to commend the CIDERU team, NCR staff, and stakeholders of the KZN-PBCR for their dedication, professionalism, and continued commitment to advancing cancer surveillance in the province.



Date: 31 March 2026

Prof Themba G. Ginindza

**(Director: Cancer & Infectious Diseases Epidemiology Research Unit (CIDERU))**

## **EXECUTIVE SUMMARY**

Cancer is a reportable disease in South Africa, highlighting the critical need for comprehensive and high-quality surveillance systems. The KwaZulu-Natal Population-Based Cancer Registry (KZN-PBCR) is the first population-based cancer registry established in KwaZulu-Natal and the second in South Africa. The establishment of the KZN-PBCR was made possible through a Memorandum of Understanding between the National Cancer Registry (NCR) and the Cancer & Infectious Diseases Epidemiology Research Unit (CIDERU), mandating CIDERU to collect population-based cancer surveillance data on behalf of the NCR. This collaboration represents a significant advancement in strengthening cancer surveillance and supporting evidence-based health planning in the province.

This report presents the second annual analysis of cancer incidence in the eThekweni district, covering all cancers diagnosed in 2024. It also marks the second consecutive year of complete data collection by the KZN-PBCR, reflecting continued progress in data completeness and system maturity.

The partnership between NCR and CIDERU has yielded several positive outcomes, including the implementation of cancer registration training programmes and workshops for KZN-PBCR staff. The registry has also expanded its stakeholder network to include private-sector partners such as the Independent Clinical Oncology Network (ICON) Oncology and the South African Oncology Consortium (SAOC), resulting in the inclusion of SAOC data in the 2024 report. Relationships with public health facilities across the eThekweni district have similarly been established and strengthened.

In 2024, a total of 3,923 cancer cases were registered, with females accounting for the majority (59.4%) of cases. Among females, the most diagnosed cancers were breast, cervical, and colorectal cancers, while among males, prostate, colorectal, and lung cancers were most diagnosed. Notably, higher incidence rates were observed among White and Asian population groups across several cancer types, pointing to disparities in healthcare access, diagnosis, and treatment—particularly affecting the Black population.

Paediatric cancers accounted for 1.0% of all cases, with 39 of 3,923 cases recorded among children aged 0–19 years. The most common paediatric cancers were lymphoma and soft tissue sarcomas. The overall proportion of morphologically verified cases was 69.6%, underscoring the KZN-PBCR's commitment to producing high-quality and reliable data.

The findings presented in this report provide critical insights into the burden and distribution of cancer within the population. These data contribute to national cancer estimates and support health system planning, policy development, and resource allocation. Collectively, data from the KZN-PBCR, the Ekurhuleni Population-Based Cancer Registry (EPBCR), and the national pathology-based cancer registry offer a comprehensive snapshot of the cancer landscape in South Africa. The consistency in leading cancer types across these registries reinforces confidence in the reliability of cancer surveillance data for informing policy and guiding healthcare interventions.

The KZN-PBCR remains committed to strengthening stakeholder partnerships and ensuring the continued production of high-quality cancer data to support effective cancer control strategies and improve population health outcomes in South Africa.

## INTRODUCTION

Globally, cancer remains a major public health challenge. In 2022, an estimated 20 million new cancer cases were diagnosed, with approximately 9.7 million cancer-related deaths reported worldwide (1). Despite this significant burden, cancer incidence and mortality are often under- or inaccurately reported in many low- and middle-income countries (LMICs) (2,3). Projections indicate that the cancer burden in these settings will increase substantially, with estimates suggesting that by 2030, nearly three-quarters of all cancer deaths will occur in LMICs (4,5). These trends highlight the urgent need for robust cancer surveillance systems to generate accurate and reliable data for planning, monitoring, and evaluation of cancer control strategies.

Cancer registration systems play a critical role in this regard, enabling the systematic collection, analysis, and interpretation of cancer data. Population-based cancer registries (PBCRs) are widely regarded as the gold standard for measuring cancer burden, as they capture all cancer cases occurring within a well-defined population (6). Such registries provide essential evidence to inform policy development, resource allocation, and health system strengthening.

In South Africa, cancer has been a reportable disease since 2011 (7). In accordance with Regulation No. 380 under the National Health Act (Act 61 of 2003), the National Cancer Registry (NCR) is mandated to establish and maintain population-based cancer registries across the country to ensure comprehensive data collection and accurate estimation of the national cancer burden. This legislative framework enabled the establishment of the KwaZulu-Natal Population-Based Cancer Registry (KZN-PBCR), the second population-based cancer surveillance site in South Africa, following the Ekurhuleni Population-Based Cancer Registry (EPBCR) in Gauteng Province (8).

The KZN-PBCR was established in 2023 through a Memorandum of Understanding between the NCR and the Cancer & Infectious Diseases Epidemiology Research Unit (CIDERU), with CIDERU mandated to collect population-based cancer surveillance data on behalf of the NCR. The NCR provides ongoing technical support to the KZN-PBCR, including stakeholder engagement, data collection, data management, and analysis.

Capacity development has been a central component of the KZN-PBCR. Team members have undergone training through the International Agency for Research on Cancer's Global Initiative for Cancer Registry Development (IARC-GICR) e-learning programmes. In addition,

participation in the African Cancer Registry Network (AFCRN) annual meeting in October 2025 provided valuable opportunities for knowledge exchange, capacity building, and strategic guidance toward future AFCRN membership. Further training and mentorship initiatives, such as the Advanced Cancer Registry and Mentorship Programme offered by the Kenyan Medical Research Institute (KEMRI), have strengthened the technical capacity of the registry team.

KwaZulu-Natal is one of the largest provinces in South Africa, with an estimated population of 4.3 million, representing approximately 6.3% of the national population. The KZN-PBCR currently covers two districts: eThekweni and Zululand. This report focuses on the eThekweni district, as data collection in the Zululand district has not yet reached the minimum threshold of 50% population coverage required for inclusion in the main analysis. The eThekweni district is predominantly urban, with the majority of the population (74%) being Black, followed by the Asian population group (18%). Future reports will incorporate data from the predominantly rural Zululand district, which has an estimated population of 923,824 (9,10).

This cancer incidence report presents findings for cancers diagnosed in 2024. A total of 4,259 cancer cases were registered by the KZN-PBCR during this period, of which 1,707 cases (40.1%) occurred in males and 2,552 cases (59.9%) in females. The majority of cases (3,923; 92.1%) were recorded in the eThekweni Metropolitan Municipality, while 336 cases (7.9%) were from the Zululand district. Accordingly, the results presented in the main body of this report focus on the eThekweni district, with findings from the Zululand district provided in Appendix 3.

## **METHODS**

The KZN-PBCR employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC), and the African Cancer Registry Network (AFCRN) in its day-to-day functioning. The KZN-PBCR employs both passive (receives reports from facilities) and active surveillance (sends cancer information officers to facilities to collect information from different sources) approach, collecting data on all cancer patients residing in eThekweni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigation.

### **Data sources**

#### **i. Government Hospitals/Healthcare Facilities**

The KZN-PBCR has multiple data sources that extend beyond the borders of the eThekweni metropolitan municipality due to the nature of the South African healthcare referral system. A municipality does not often have all levels of care (level 1: Primary healthcare clinic, Community healthcare centre, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (11). Therefore, patients may be referred out of or into the municipality to access further diagnosis and management. Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which may not necessarily be within the borders of the district in which they reside.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen percent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, to obtain complete reporting from the eThekweni municipality population, the KZN-PBCR also collects data from clinicians in independent private practice (See Appendix 1 for a comprehensive list of data sources).

#### **ii. Laboratories, Oncology Networks and Associations**

South Africa has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has over 200 laboratories in nine provinces of SA (12). The other estimated 20% of the

population is covered by private laboratories which include but are not limited to Ampath, Pathcare and Lancet laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer to the NCR's national pathology surveillance programme. The cancer information officers use all the pathology reports received from laboratories together with other data tools (medical files, hospital register, pharmacy list etc.) to identify, trace and register patients from eThekweni municipality into the KZN-PBCR.

In addition, the ICON Oncology and South African Oncology Consortium (SAOC) report their relevant data for residents of the eThekweni municipality to the NCR. The cancer information officers use these data sources to consolidate missing information for patients already registered in the KZN-PBCR database in conjunction with other data tools from different data sources. Finally, cancer information officers use hospital registers, patient files, and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

**iii. Vital Statistics (Death Registration)**

Statistics South Africa (STATS SA) is unable to share patient-level data with other official organisations legally. To compensate for the challenge, the cancer information officers visit the mortuaries within healthcare facilities to trace and report cases of cancer for patients who may have been missed while alive.




Figure 1: KwaZulu-Natal Population-based cancer registry data sources map, 2024

### Data Collection and Processes

The KZN-PBCR uses both active and passive methods of case finding.

Active case finding:

- The surveillance officers visit healthcare facilities to review electronic and or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinicians’ statistical records to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

- As mentioned above, ICON Oncology and SAOC passively provides data to the NCR that is shared with KZN-PBCR.

Inclusion criteria for both active and passive case-finding methods:

- All confirmed cancer cases, persons who are residents of the eThekweni metropolitan municipality diagnosed from 1<sup>st</sup> January to 31<sup>st</sup> December of the relevant year must be reported to the registry.
- Cancer cases include:
  - Cases considered malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behaviour code-3 are reported to the registry.
  - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumour site topography. If this is not known, it is registered as an unknown primary site.

The cancer information officers extract data/variables required (See Appendix 2: South African Cancer Registration Form) from data sources such as medical records and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3<sup>rd</sup> edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then captured onto the REDCap system. The UKZN-CIDERU uses REDCap because of the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.

The captured files are sent to the cancer registrar manager for quality assurance and quality control. The cancer registrar manager uses the electronic records on Redcap for each cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years, as per the South Africa Protection of Personal Information Act (POPI Act) before they are permanently destroyed (13). The complete, quality-assured dataset is extracted per year (1<sup>st</sup> January to 31<sup>st</sup> December for each year) for cleaning and analysis using Stata software. The analysed data are then used for annual incidence reports, teaching/training, and research purposes. Figure 2 illustrates the data processing and flow for the KZN-PBCR.

# Data Flow Lifecycle: The KwaZulu-Natal Population-Based Cancer Registry

A systematic 7-step process used to collect, validate, and report cancer data for the Minister of Health, focusing on eThekweni and Zululand regions.




Figure 2: KwaZulu-Natal Population-Based Cancer Registry data flow diagram, 2024

## Confidentiality

The UKZN-CIDERU and NCR adhere to the NHLS, the IARC/IACR guidelines and the POPI Act to ensure the preservation of privacy during the KZN-PBCR surveillance process (13). Request to use de-identified individual-level KZN-PBCR data by entities/individuals is sought

in writing to the UKZN-CIDERU and NCR. Ethics approval is required before data is granted. The statistics of cancer data are released in an aggregated format through the annual reports published on the UKZN-CIDERU and NCR websites.

## Statistical Analysis

The results are presented as:

- the number of new cancer cases,
- the proportion (percentage) of all new cancer cases,
- Age-standardised incidence rate (ASR) per 100,000, and
- The lifetime risk
- Age-standardised incidence rate (ASR) per million for paediatric cancers

The results are further stratified by:

- sex (male and female),
- population group (Black, White, Asian and Coloured) and
- age groups (5-year interval, e.g.0-4 years, 5-9, 10-14, etc.).

For age standardization, the Segi World Standard Population (WSP) is used as per international cancer registration norms. STATS SA mid-year population data for municipalities is used as a denominator.

The calculation methods are as follows:

$$\text{Crude} = \frac{\text{Number of new cases}}{\text{Mid-year population}} \times 100,000$$

$$\text{WSP weighting} = \frac{\text{WSP (for each age group)}}{\text{Total WSP for all age groups}} \times 100,000$$

$$\text{ASR} = \text{Crude} \times \text{WSP weighting}$$

Benign growths, in-situ lesions, and cancers of unknown behaviour were excluded from the data collection and analysis.

## RESULTS

### Overall cancer incidence

A total of 3,923 cancer cases were registered by the KZN-PBCR (eThekweni district) for the year 2024, with 1,593 cases (40.6%) occurring in males and 2,330 (59.4%) occurring in females. Figure 3 below shows the percentage of cancer cases diagnosed in 2024 by sex and population group. Forty-five percent (45%) of cases were diagnosed among the Black population, 27.5% among the Asian population, 25.3% among the White population, and 2.2% was diagnosed among the Coloured population group.




Figure 3: Percentage of cancer cases by sex and population group, KZN-PBCR 2024.

Tables 1 and 2 illustrate a detailed tabulation of cases registered in 2024 for males and females. The tables show the total number of cases registered, crude rates per 100 000 population, age-adjusted incidence rates per 100 000 population, and lifetime risk for each cancer. Appendix tables further elaborate on these data by demonstrating frequency, age-standardised and age-specific incidence rates by population group and sex.

Table 1: Summary statistics for all cancers in Males, KZN PBCR 2024

SITE	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	1593	73,26	67,02	7	14
All sites but skin	1286	59,28	54,27	6	17
Prostate	411	18,90	17,08	2	47
SCC Skin	276	12,69	11,56	1	82
Colorectal	144	6,62	5,95	1	145
Lung	116	5,33	4,93	1	166
Haematology other	44	2,02	1,85	0	521
Bladder	43	1,98	1,77	0	487
Primary site unknown	40	1,84	1,78	0	628
Stomach	40	1,84	1,67	0	542
Larynx	34	1,56	1,50	0	709
BCC	31	1,43	1,35	0	750
Oesophagus	31	1,43	1,34	0	616
Non Hodgkin lymphoma	29	1,33	1,25	0	803
Pancreas	29	1,33	1,27	0	710
Naso-Oropharynx	25	1,15	1,02	0	862
Brain, CNS	23	1,06	0,99	0	1213
Other specified	23	1,06	0,92	0	901
Liver & Bile duct	22	1,01	0,88	0	956
Kaposi Sarcoma	21	0,97	0,74	0	1458
Kidney	19	0,87	0,86	0	956
Mouth	17	0,78	0,74	0	1270
Testis	17	0,78	0,73	0	2011
Penis	16	0,74	0,69	0	1568
Bone	14	0,64	0,63	0	1786
Connective tissue	14	0,64	0,64	0	1669
Melanoma	14	0,64	0,64	0	1492
Tongue	14	0,64	0,60	0	1375
Breast	10	0,46	0,41	0	2334

Ill defined	9	0,41	0,40	0	3063
Myeloma	9	0,41	0,39	0	2458
Eye	8	0,37	0,38	0	2920
Leukaemia	8	0,37	0,32	0	2191
Thyroid	8	0,37	0,31	0	2942
Anus	6	0,28	0,24	0	3585
Hodgkin lymphoma	6	0,28	0,29	0	3781
Salivary gland	6	0,28	0,24	0	3111
Endocrine	5	0,23	0,20	0	5334
Small intestine	4	0,18	0,16	0	3945
Lip	3	0,14	0,12	0	8929
Mesothelioma	3	0,14	0,11	0	7327
Burkitt lymphoma	1	0,05	0,06	0	33334

Table 2: Summary statistics for all cancers in Females, KZN PBCR 2024

SITE	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	2330	107,01	121,12	12	8
All sites but skin	1954	91,99	102,94	11	9
Breast	650	29,85	34,20	4	27
Cervix	363	16,67	16,86	2	55
SCC Skin	355	16,30	19,48	2	50
Colorectal	129	5,92	7,59	1	137
Uterus	110	5,05	6,18	1	128
Vulva	81	3,72	3,55	0	305
Ovary	57	2,62	2,80	0	277
Lung	51	2,34	2,96	0	272
Oesophagus	45	2,07	2,56	0	327
Primary site unknown	38	1,75	2,16	0	601
Haematology other	35	1,61	1,86	0	497
Brain, CNS	30	1,38	1,57	0	624
Thyroid	27	1,24	1,15	0	756
Non Hodgkin Lymphoma	25	1,15	1,11	0	903
Liver & Bile duct	23	1,06	1,20	0	913
Naso-Oropharynx	23	1,06	1,15	0	1056
Stomach	23	1,06	1,19	0	594
Other specified	21	0,96	1,16	0	903
BCC	20	0,92	1,24	0	1194
Pancreas	19	0,87	1,10	0	1049
Vagina	17	0,78	0,93	0	878
Kaposi Sarcoma	16	0,73	0,59	0	1965
Ill defined	15	0,69	0,66	0	1528
Melanoma	15	0,69	0,81	0	1020
Bladder	14	0,64	0,83	0	1492

Mouth	12	0,55	0,65	0	926
Connective tissue	11	0,51	0,58	0	2532
Endocrine	10	0,46	0,47	0	2003
Hodgkin lymphoma	10	0,46	0,41	0	2678
Tongue	10	0,46	0,49	0	1564
Kidney	9	0,41	0,51	0	2286
Leukaemia	7	0,32	0,51	0	3425
Myeloma	7	0,32	0,35	0	2248
Salivary gland	7	0,32	0,26	0	4256
Bone	5	0,23	0,21	0	6945
Larynx	4	0,18	0,18	0	7273
Small intestine	4	0,18	0,19	0	2924
Eye	3	0,14	0,15	0	10472
Gum	2	0,09	0,17	0	16261
Mesothelioma	2	0,09	0,11	0	4808
Placenta	2	0,09	0,06	0	21277
Burkitt lymphoma	1	0,05	0,03	0	41667
Lip	1	0,05	0,04	0	33334
Anus	0	0,96	0,91	0	1197

Figure 4-7 below illustrates the frequency and age-standardised incidence rates of the most common cancers registered in the KZN-PBCR in 2024 for males and females. Prostate cancer was by far the most common cancer amongst males with 411 cases and an ASR of 17.08/100 000 population. Amongst females, breast cancer was leading with 650 new cases reported with an ASR of 34.20/100 000. Figures 8 and 9 illustrate the top 5 cancers ASRs by population group. In males, the Asian population group had the highest ASR in prostate cancer followed by White, Black and then Coloured population groups. In females, the Asian population group had the highest ASR in breast cancer, followed by White, Black, and then Coloured population groups.




Figure 4: Frequency of most common cancers in males, KZN-PBCR 2024




Figure 5: Age Standardised Incidence Rates for the most common cancers in males, KZN-PBCR 2024




Figure 6: Frequency of most common cancers in females, KZN-PBCR 2024




Figure 7: Age-standardised incidence rates for common cancers in females, KZN-PBCR 2024




Figure 8: ASR for top 5 cancers in males by population group, KZN-PBCR 2024




Figure 9: ASR for top 5 cancers in females by population group, KZN-PBCR 2024

### Comparison of cancer incidence across the years 2023- 2024

Figures 10 and 11 show a comparison of ASRs for common cancer cases from 2023 to 2024 by sex. Figure 12 shows comparisons of case numbers from 2023 to 2024. There was a 31.9% increase in the number of cancer cases reported in 2024 (n=3,923) compared with 2023 (n=,2795). Among males, there was a 64.4% increase, while among females, there was a 29.9% increase. The pattern of the most common top 5 cancers age-standardised incidence rates by sex remained comparable between the two years (2023/4).




Figure 10: ASRs for most common cancers in men, 2023-2024




Figure 11: ASRs for most common cancers in women, 2023-2024




Figure 12: Number of cancer cases reported by year and sex, KZN-PBCR 2023-2024

## Childhood cancer incidence

Table 3 below shows the top 10 cancers in children aged 0-19 in the eThekweni district. Thirty-nine cancers were registered among children in 2024. Paediatric cancers accounted for 1.0% of all cancers registered in 2024. There were 22 cancers in boys and 17 cancers in girls. Lymphoma, soft tissue sarcomas, CNS neoplasms, and neuroblastoma were the most common cancers in children.

Table 3: Childhood cancers, KZN-PBCR 2024

Cancer	Number of cases					M/F ratio	Rates per Million Age-Specific Rates				Crude	ASR	LCL	UCL
	Age 0-04	Age 05-09	Age 10-14	Age 15-19	All		Age 0-04	Age 05-09	Age 10-14	Age 15-19				
Leukaemia	0	0	1	0	1	0	0	0	3	0	0,71	0,64	0,02	3,79
Lymphoma	0	1	1	3	5	2	0	3	3	9	3,57	3,31	1,07	7,83
CNS Neoplasms	1	0	1	1	3	2	3	0	3	3	2,14	2,11	0,43	6,22
Neuroblastoma	1	0	0	0	1	0	3	0	0	0	0,71	0,83	0,02	4,31
Retinoblastoma	2	0	0	0	2	1	6	0	0	0	1,43	1,66	0,20	5,72
Nephroblastoma - Wilms Tumour	1	1	1	0	3	2	3	3	3	0	2,14	2,21	0,45	6,43
Bone Tumours	0	0	0	0	0	0	0	0	0	0	0,00	0,00	0,00	2,64
Soft Tissue Sarcomas	2	2	0	1	5	4	6	6	0	3	3,57	3,77	1,22	8,74
Germ Cell Tumours	0	0	0	1	1	0	0	0	0	3	0,71	0,64	0,02	3,79
Primary site unknown	0	0	0	0	0	0	0	0	0	0	0,00	0,00	0,00	2,64
Other, specified	2	3	3	10	18	1	6	9	9	29	12,84	12,22	7,22	19,39
<b>All sites</b>	<b>9</b>	<b>7</b>	<b>7</b>	<b>16</b>	<b>39</b>	<b>12</b>	<b>25</b>	<b>21</b>	<b>20</b>	<b>46</b>	<b>28</b>	<b>27</b>	<b>11</b>	<b>71</b>

## Data Quality Indicators

### a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases that were morphologically verified (MV) using histology, cytology, or bone marrow aspirate and trephine, diagnosed by clinical means or registered from death certificate-only information (DCO).

Table 4: Percentage of cases Morphologically Verified (MV), diagnosed clinically or diagnosed by Death Certificate Only (DCO), KZN-PBCR 2024.

ICD 10 Cancer Site	Cases		Basis of Diagnosis			
	No. of Cases	% Total	DCO	Clinical	MV	Unknown
Anus	27.0	0.7	0.0	3.7	85.2	11.1
BCC	51.0	1.3	0.0	3.9	96.1	0.0
Bladder	57.0	1.5	0.0	3.5	70.2	26.3
Bone	19.0	0.5	0.0	0.0	78.9	21.1
Brain, CNS	53.0	1.4	0.0	9.4	49.1	41.5
Breast	660.0	16.8	0.0	1.2	68.2	30.6
Cervix	363.0	9.3	0.0	0.8	89.5	9.6
Colorectal	273.0	7.0	0.0	0.7	68.1	31.1
Connective tissue	25.0	0.6	0.0	0.0	60.0	40.0
Endocrine	15.0	0.4	0.0	20.0	60.0	20.0
Eye	11.0	0.3	0.0	27.3	54.5	18.2
Gum	2.0	0.1	0.0	0.0	50.0	50.0
Haematology other	79.0	2.0	0.0	38.0	43.0	19.0
Hodgkin lymphoma	16.0	0.4	0.0	43.8	56.2	0.0
Ill defined	24.0	0.6	0.0	12.5	75.0	12.5
Kaposi Sarcoma	37.0	0.9	0.0	2.7	97.3	0.0
Kidney	28.0	0.7	0.0	3.6	46.4	50.0
Larynx	38.0	1.0	0.0	0.0	73.7	26.3
Leukaemia	15.0	0.4	0.0	86.7	13.3	0.0
Lip	4.0	0.1	0.0	0.0	100.0	0.0
Liver & Bile duct	45.0	1.1	0.0	13.3	64.4	22.2
Lung	167.0	4.3	0.0	4.2	71.9	24.0
Melanoma	29.0	0.7	0.0	3.4	96.6	0.0
Mesothelioma	5.0	0.1	0.0	0.0	100.0	0.0

Mouth	29.0	0.7	0.0	0.0	82.8	17.2
Myeloma	16.0	0.4	0.0	68.8	31.2	0.0
Naso-Oropharynx	48.0	1.2	0.0	6.2	77.1	16.7
Non Hodgkin lymphoma	54.0	1.4	0.0	42.6	57.4	0.0
Oesophagus	76.0	1.9	0.0	3.9	86.8	9.2
Other specified	44.0	1.1	0.0	2.3	65.9	31.8
Ovary	57.0	1.5	0.0	26.3	56.1	17.5
Pancreas	48.0	1.2	0.0	6.2	62.5	31.2
Penis	16.0	0.4	0.0	0.0	87.5	12.5
Placenta	2.0	0.1	0.0	0.0	50.0	50.0
Primary site unknown	78.0	2.0	0.0	26.9	55.1	17.9
Prostate	411.0	10.5	0.0	1.2	69.1	29.7
Salivary gland	13.0	0.3	0.0	7.7	53.8	38.5
SCC Skin	631.0	16.1	0.0	27.6	61.2	11.3
Small intestine	8.0	0.2	0.0	0.0	75.0	25.0
Stomach	63.0	1.6	0.0	0.0	69.8	30.2
Testis	17.0	0.4	0.0	11.8	58.8	29.4
Thyroid	35.0	0.9	0.0	5.7	51.4	42.9
Tongue	24.0	0.6	0.0	0.0	62.5	37.5
Uterus	110.0	2.8	0.0	0.9	75.5	23.6
Vagina	17.0	0.4	0.0	0.0	94.1	5.9
Vulva	81.0	2.1	0.0	0.0	95.1	4.9
Burkitt lymphoma	2.0	0.1	0.0	0.0	100.0	0.0
<b>Total</b>	<b>3,923.0</b>	<b>100.0</b>	<b>0.0</b>	<b>9.3</b>	<b>69.6</b>	<b>21.1</b>

Abbreviations: BCC- Basal Cell Carcinoma, CNS- Central Nervous System

#### **b) Primary site unknown (PSU)**

There were 124 cases of cancer (3.1%) reported where the primary site was unspecified or uncertain from the available documentation. The rates of PSU were 1.78 and 2.16 /100 000 in males and females, respectively.

#### **c) Age unknown**

There was no record with unknown age

## DISCUSSION

This report marks the second year of completed data collection by the KwaZulu-Natal Population-Based Cancer Registry (KZN-PBCR). The eThekweni Metropolitan Municipality, which constitutes the focus of this report, represents approximately 6.3% of the South African population and provides a diverse urban setting reflective of the country's demographic composition. The KZN-PBCR case definition includes all confirmed cancer cases—diagnosed through pathological, clinical, or radiological means—among residents of both the eThekweni Metropolitan and Zululand Districts; however, the present analysis is restricted to the eThekweni Metropolitan area.

Population-based cancer registries (PBCRs) are regarded by the World Health Organization as the gold standard for cancer surveillance due to their systematic use of multiple data sources to ensure completeness and validity of data (14). In the KZN-PBCR, 69.9% of cases were morphologically verified, while 9.3% were derived from clinical records. Notably, 21% of cases lacked a recorded basis of diagnosis, highlighting a critical area for data quality improvement, particularly within passively collected data systems. Nonetheless, the integration of multiple data sources—including pathology, clinical, and private sector data—has significantly enhanced overall data completeness and reliability.

The pattern of commonly diagnosed cancers in the KZN-PBCR is broadly consistent with findings from the Ekurhuleni Population-Based Cancer Registry and global estimates (1,15). Among children (0–19 years), lymphoma and soft tissue sarcomas were the most frequently diagnosed cancers in KwaZulu-Natal. This contrasts with findings from the EPBCR, where nephroblastoma and CNS neoplasms were the leading childhood cancers in 2023. These differences may reflect variations in case ascertainment, referral patterns, or underlying population characteristics.

The observed increase in cancer incidence in this reporting period is largely attributable to the expansion of data sources. The inclusion of data from the South African Oncology Consortium and Ampath Laboratories—which were not part of the previous reporting cycle—has substantially increased private sector representation. This has, in turn, influenced the demographic profile of reported cases, including a higher proportion of individuals classified as White. Age-specific trends indicate an increasing incidence of cancer with advancing age in this group, particularly among those aged 70 years and older. In contrast, a decline in incidence

with age was observed among the Black population in the same age category. These patterns may reflect differences in life expectancy, access to healthcare, health-seeking behaviour, and competing mortality risks, as well as broader socioeconomic determinants of health (16,17).

Another contributor to the observed increase in cancer incidence in the current reporting period should be interpreted in the context of significant disruptions to data collection in 2023 and 2024 following a cyberattack on the NHLS. This event necessitated the outsourcing of laboratory services and resulted in many records being returned in manual formats, delaying digital capture. Consequently, the 2023 data reflects an artificial decline due to incomplete reporting, while the 2024 data shows an apparent increase following retrospective back-capturing. For instance, the prostate cancer age-standardised incidence rate (ASR) rose from 1.62 to 17.08 per 100,000, representing a technical artefact rather than a true rise in incidence. This effect is further accentuated by the sensitivity of prostate cancer incidence to variations in screening practices, particularly PSA testing.

KwaZulu-Natal is also characterised by a comparatively large Asian/Indian population, which accounted for approximately 27.5% of reported cases in 2024—an increase from 23% in the previous reporting period. This is substantially higher than the 2% reported by the EPBCR in 2023. The relatively higher cancer incidence observed in this population group may be associated with improved access to healthcare services, higher socioeconomic status, and greater utilisation of diagnostic services. Conversely, the Black population accounted for the majority (55%) of cancer cases, underscoring the importance of KZN as a sentinel site for capturing cancer burden among historically underrepresented populations in South Africa (18-20). These data provide critical insights into cancer epidemiology across diverse population groups, including the Asian/Indian community, which remains underrepresented in national datasets.

Although data from the Zululand District remain limited, the observed distribution of common cancers—such as cervical, prostate, and breast cancers—reflects patterns consistent with those seen at both national and global levels. The relatively high number of cervical cancer cases observed among females may partly reflect data collection activities at Queen Nandi Regional Hospital, a facility with a strong focus on women’s health services.

Operational and logistical challenges in the Zululand District continue to limit the completeness of data from this region. Data collection has largely relied on referral facilities

located outside the district, including Ngwelezana Tertiary Hospital and Queen Nandi Regional Hospital, both of which serve multiple districts. This complicates accurate attribution of cases to Zululand residents. Furthermore, incomplete recording of patient residential addresses in medical records has hindered precise geographic classification, resulting in potential underestimation of the cancer burden in the district. Encouragingly, improvements in address recording have resulted in a 69.7% increase in usable geographic data compared to 2023.

To address these limitations, the KZN-PBCR aims to strengthen data collection within Zululand by expanding active case-finding efforts at local health facilities. Securing additional funding to support dedicated personnel across the district's five health facilities will be critical to improving coverage, data quality, and representativeness.

## **CONCLUSION**

The KZN-PBCR has successfully produced its second annual cancer incidence report, representing a significant step forward in strengthening cancer surveillance in KwaZulu-Natal. Population-based cancer registration remains essential for understanding the burden of cancer, informing public health planning, and guiding resource allocation for prevention, diagnosis, and treatment services.

In this reporting period, the most diagnosed cancers among males were prostate, colorectal and lung cancers, while breast, cervical, and colorectal cancers predominated among females. Among children (0–19 years), lymphoma and soft tissue sarcomas were the leading cancer types. These findings are broadly consistent with national and global cancer patterns.

The continued expansion and integration of multiple data sources have improved the completeness and representativeness of the registry. Future efforts will focus on sustaining annual data collection, enhancing data quality, and integrating findings with other population-based cancer registries in South Africa to generate more robust national cancer incidence estimates.

Importantly, strengthening rural data collection—particularly in the Zululand District—remains a key priority. Expanding active data collection within local facilities and securing additional resources will be essential to achieving comprehensive geographic coverage. The inclusion of rural populations will significantly enhance the representativeness of the registry

and contribute to a more accurate understanding of cancer epidemiology across KwaZulu-Natal.

## **ACKNOWLEDGEMENTS**

This work has been possible through funding provided by the Bristol Myers Squibb Foundation (BMSF). The UKZN-CIDERU would also like to thank the National Cancer Registry of South Africa for its continuous support.

The Cancer and Infectious Disease Epidemiology Research Unit (CIDERU) situated in UKZN would also like to thank all individuals, organizations, and relevant stakeholders who played a critical role in the operations of the KwaZulu-Natal Population-Based Cancer Registry.

African Cancer Registry Network (AFCRN)

Addington Hospital

Greys Hospital

Inkosi Albert Luthuli Central Hospital

Ngwelezana Tertiary Hospital

National Department of Health South Africa

National Health Laboratory Services

National Institute for Communicable Diseases

Queen Nandi Regional Hospital

ICON Oncology

Eldoret Cancer Registry

International Agency for Research on Cancer (IARC)

International Association of Cancer Registries (IACR)

South African Oncology Consortium (SAOC)

World Health Organization (WHO)

## REFERENCES

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024 May;74(3):229–63.
2. Jemal A, Bray F, Ferlay J. Global Cancer Statistics: 2011. *CA Cancer J Clin* [Internet]. 1999;49(2):1,33-64. Available from: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10200776](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10200776)
3. Sartorius B, Sartorius K. How much incident lung cancer was missed globally in 2012? An ecological country-level study. *Geospat Health*. 2016;11(396):110–8.
4. Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, et al. Priorities for cancer research in low- and middle-income countries: a global perspective. *Nat Med*. 2022;28(4):649–57.
5. The global cancer observatory. <https://gco.iarc.fr/tomorrow/en>. Cited on 30 August 2022. 2022. International Agency for Research on Cancer, WHO. Available from: [gco.iarc.fr](https://gco.iarc.fr)
6. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration: principles and methods. *IARC Sci Publ* [Internet]. 1991;(95):1–288. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/1894333>
7. Department of Health SA. National Health Act, 2003 (Act no. 61 of 2003): Regulations 380 Cancer registration. 2011.
8. National Cancer Registry SAfrica. Ekurhuleni Population-Based Cancer Registry 2018 Annual report [Internet]. 2020. Available from: [www.ncr.ac.za](http://www.ncr.ac.za).
9. Department of Cooperative Governance and Traditional Affairs. eThekweni Metropolitan, KZN. 2020.
10. Cooperative governance and traditional affairs. Zululand District Municipality, KZN [Internet]. 2020 [cited 2025 Mar 26]. Available from: [https://www.cogta.gov.za/cgta\\_2016/wp-content/uploads/2023/11/DistrictProfile\\_ZULULAND08072020-1.pdf](https://www.cogta.gov.za/cgta_2016/wp-content/uploads/2023/11/DistrictProfile_ZULULAND08072020-1.pdf)
11. Department of Health. Referral policy for South Africa health services and referral implementation guidelines. Vol. 8, *International Ayurvedic Medical Journal*. 2020.

12. NHLS. 2022-2023 NHLS Annual Report. 2024 [cited 2025 Mar 6]; Available from: <https://www.nhls.ac.za/key-documents/annual-reports/>
13. Parliament of the Republic of south Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013 Apr.
14. World Health Organization. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer; 1991. (IARC Scientific Publication No. 95).
15. NCR. Ekurhuleni population-based cancer registry 2023 Report [Internet]. 2025. Available from: <https://www.nicd.ac.za/centres/national-cancer-registry/>
16. World Health Organization. Social determinants of health. Geneva: WHO; 2023.
17. Statistics South Africa. Inequality trends in South Africa: A multidimensional diagnostic of inequality. Pretoria: Stats SA; 2019.
18. Scott D, Curtis B, Twumasi FO. Towards the creation of a health information system for cancer in KwaZulu-Natal, South Africa. *Health Place* [Internet]. 2002;8(4):237–49.
19. Mbeje NP, Ginindza TG, Jafta N. Establishing and Evaluating Cancer Surveillance System in KwaZulu-Natal , South Africa. *Cancer Inform*. 2021;20:1–11.
20. Motlana MKTN, Ginindza TG, Mitku AA, Jafta N. Spatial Distribution of Cancer Cases Seen in Three Major Public Hospitals in KwaZulu-Natal , South Africa. *Cancer Inform*. 2021;20:1–12.

# APPENDICES

## Appendix 1: List of Data Sources

### **PUBLIC HOSPITALS**

- Addington Hospital
- Greys Hospital
- Inkosi Albert Luthuli Central Hospital
- Ngwelezana Tertiary Hospital
- Queen Nandi Regional Hospital

### **ICON ONCOLOGY**

- ❖ Private Oncologists

South African Oncology Consortium (SAOC)

- ❖ Private Oncologists

### **NHLS**

- ❖ CDW pathology-based cancer reports



### Appendix 3: Zululand District Statistics

The Zululand district registered 336 cancer cases for the year 2024, 114 cases (34%) occurring in males and 222 (66%) occurring in females. Benign growths, in-situ lesions, and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 13 below shows the percentage of cancer cases diagnosed in 2024 by sex and population group. Ninety-two percent of cases were diagnosed among the Black population, 6% among the White population and 0.9% among the Asian population.




Figure 13: Percentage of cancer cases by sex and population group, Zululand district 2024.

Figures 14 and 15 below illustrate the most common cancers registered in the Zululand district in 2024 for males and females. The most common cancers registered for males were prostate, colorectal, lung, and Kaposi Sarcoma cancers. Among females, cervix, breast, vulva, uterus, and colorectal cancer were the most common cancers.




Figure 14: Frequency of most common cancers in males, Zululand district 2024




Figure 15: Frequency of most common cancers in females, Zululand district 2024

## Appendix 4: Tables of Incidence by site, sex, age group and population, 2024

### Tables of ASR and Crude Incidence by population group

Asian Females: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Breast	153	33,55	245	443,06	271,62	238,09	309,52
Squamous cell carcinoma of skin	97	21,27	124	224,24	143,93	119,23	173,22
Colorectal	34	7,46	55	99,46	62,62	46,42	83,70
Uterus	21	4,61	35	63,29	36,37	25,17	52,35
Cervix	8	1,75	29	52,44	33,93	22,68	50,14
Ovary	11	2,41	22	39,78	27,71	16,88	43,93
Lung	15	3,29	18	32,55	18,43	10,78	31,17
Thyroid	7	1,54	13	23,51	15,75	8,36	28,54
Primary site unknown	12	2,63	10	18,08	11,11	5,27	22,47
Haematology other	7	1,54	10	18,08	9,78	4,60	20,43
Other specified	6	1,32	8	14,47	9,42	4,06	20,46
Non Hodgkin lymphoma	6	1,32	7	12,66	8,78	3,52	19,88
Stomach	4	0,88	8	14,47	8,74	3,71	19,45
Brain, CNS	9	1,97	8	14,47	8,74	3,72	19,42
Mouth	1	0,22	7	12,66	7,82	3,12	18,29
Pancreas	11	2,41	6	10,85	5,83	2,05	15,50
Naso-Oropharynx	5	1,10	4	7,23	4,96	1,35	14,82
Tongue	1	0,22	5	9,04	4,93	1,55	14,35
Liver & Bile duct	2	0,44	4	7,23	4,68	1,26	14,33
Ill defined	1	0,22	4	7,23	4,57	1,23	14,15
Bladder	0	0,00	4	7,23	4,01	1,05	13,20
Salivary gland	1	0,22	3	5,43	3,64	0,75	13,02
Vagina	3	0,66	3	5,43	3,00	0,61	11,85
Oesophagus	3	0,66	3	5,43	2,90	0,56	11,74
Endocrine	0	0,00	2	3,62	2,33	0,28	11,20
Anus	3	0,66	2	3,62	2,28	0,28	11,11
Hodgkin lymphoma	0	0,00	2	3,62	2,16	0,26	10,87
Mesothelioma	0	0,00	2	3,62	2,15	0,25	10,86
Vulva	1	0,22	2	3,62	1,58	0,18	9,88
Placenta	0	0,00	1	1,81	1,29	0,03	9,92
Small intestine	1	0,22	1	1,81	1,20	0,03	9,73
Connective tissue	1	0,22	1	1,81	1,11	0,03	9,55
Leukaemia	3	0,66	1	1,81	1,11	0,03	9,55
Gum	1	0,22	1	1,81	1,11	0,03	9,55
Kidney	5	1,10	1	1,81	0,64	0,02	8,75
Myeloma	3	0,66	1	1,81	0,64	0,02	8,75
<b>All site</b>	<b>436</b>	<b>96</b>	<b>652</b>	<b>1179</b>	<b>731</b>	<b>527</b>	<b>1156</b>

Black Females: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Cervix	320	27,44	320	18,07	17,57	15,65	19,66
Breast	229	19,64	229	12,93	13,06	11,37	14,93
Squamous cell carcinoma of skin	128	10,98	128	7,23	7,40	6,14	8,85
Vulva	77	6,60	77	4,35	4,03	3,16	5,07
Uterus	50	4,29	50	2,82	3,18	2,35	4,21
Oesophagus	39	3,34	39	2,20	2,47	1,74	3,40
Colorectal	34	2,92	34	1,92	2,13	1,44	3,01
Ovary	24	2,06	24	1,36	1,44	0,91	2,16
Lung	17	1,46	17	0,96	1,13	0,64	1,81
Liver & Bile duct	17	1,46	17	0,96	0,96	0,54	1,56
Primary site unknown	16	1,37	16	0,90	0,94	0,53	1,54
Haematology other	17	1,46	17	0,96	0,90	0,52	1,46
Brain, CNS	13	1,11	13	0,73	0,75	0,39	1,32
Naso-Oropharynx	14	1,20	14	0,79	0,75	0,39	1,30
Kaposi Sarcoma	16	1,37	16	0,90	0,74	0,42	1,24
Anus	15	1,29	15	0,85	0,71	0,39	1,20
Vagina	11	0,94	11	0,62	0,68	0,33	1,24
Bladder	10	0,86	10	0,56	0,62	0,29	1,16
Stomach	10	0,86	10	0,56	0,61	0,29	1,13
Non Hodgkin lymphoma	12	1,03	12	0,68	0,59	0,30	1,06
Melanoma	9	0,77	9	0,51	0,54	0,23	1,04
Ill defined	10	0,86	10	0,56	0,52	0,25	0,99
Connective tissue	9	0,77	9	0,51	0,49	0,22	0,95
Endocrine	8	0,69	8	0,45	0,44	0,19	0,89
Other specified	7	0,60	7	0,40	0,39	0,15	0,82
Hodgkin lymphoma	8	0,69	8	0,45	0,39	0,16	0,80
BCC	7	0,60	7	0,40	0,33	0,13	0,71
Thyroid	6	0,51	6	0,34	0,30	0,11	0,68
Bone	5	0,43	5	0,28	0,27	0,09	0,64
Mouth	4	0,34	4	0,23	0,25	0,07	0,63
Leukaemia	3	0,26	3	0,17	0,23	0,04	0,66
Eye	3	0,26	3	0,17	0,18	0,04	0,53
Kidney	3	0,26	3	0,17	0,17	0,03	0,52
Myeloma	3	0,26	3	0,17	0,17	0,03	0,51
Salivary gland	3	0,26	3	0,17	0,15	0,03	0,46
Small intestine	2	0,17	2	0,11	0,11	0,01	0,41
Tongue	2	0,17	2	0,11	0,09	0,01	0,38
Pancreas	1	0,09	1	0,06	0,06	0,00	0,33
Lip	1	0,09	1	0,06	0,05	0,00	0,30
Burkitt lymphoma	1	0,09	1	0,06	0,04	0,00	0,28
Larynx	1	0,09	1	0,06	0,04	0,00	0,28
Placenta	1	0,09	1	0,06	0,04	0,00	0,28
<b>All sites</b>	<b>1166</b>	<b>100</b>	<b>1166</b>	<b>66</b>	<b>66</b>	<b>50</b>	<b>90</b>

Coloured Females: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	23	41,07	23	12,30	9,83	6,20	14,93
Squamous cell carcinoma of skin	6	10,71	6	3,21	2,61	0,94	5,91
Cervix	6	10,71	6	3,21	2,49	0,89	5,70
Colorectal	6	10,71	6	3,21	2,42	0,88	5,53
Uterus	4	7,14	4	2,14	1,49	0,40	4,19
BCC	2	3,57	2	1,07	1,00	0,11	3,72
Tongue	2	3,57	2	1,07	0,82	0,10	3,29
Haematology other	1	1,79	1	0,53	0,59	0,01	3,15
Lung	1	1,79	1	0,53	0,53	0,01	2,97
Thyroid	1	1,79	1	0,53	0,42	0,01	2,68
Anus	1	1,79	1	0,53	0,40	0,01	2,65
Stomach	1	1,79	1	0,53	0,34	0,01	2,50
Vulva	1	1,79	1	0,53	0,34	0,01	2,50
Pancreas	1	1,79	1	0,53	0,30	0,01	2,41
<b>All sites</b>	<b>56</b>	<b>100</b>	<b>56</b>	<b>30</b>	<b>24</b>	<b>10</b>	<b>62</b>

White Females: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	245	37,58	153	94,88	45,91	38,32	55,12
Squamous cell carcinoma of skin	124	19,02	97	60,15	25,38	20,09	32,31
Colorectal	55	8,44	34	21,08	9,25	6,14	14,21
Uterus	35	5,37	21	13,02	6,71	3,96	11,46
Thyroid	13	1,99	7	4,34	3,46	1,24	8,14
Cervix	29	4,45	8	4,96	3,39	1,38	7,69
Lung	18	2,76	15	9,30	3,24	1,76	6,83
Brain, CNS	8	1,23	9	5,58	3,16	1,39	7,16
Ovary	22	3,37	11	6,82	2,82	1,32	6,51
Primary site unknown	10	1,53	12	7,44	2,80	1,29	6,51
Pancreas	6	0,92	11	6,82	2,72	1,25	6,41
Non Hodgkin lymphoma	7	1,07	6	3,72	2,49	0,84	6,53
BCC	0	0,00	11	6,82	2,37	1,11	5,86
Melanoma	0	0,00	6	3,72	2,25	0,59	6,50
Other specified	8	1,23	6	3,72	1,59	0,51	5,12
Kidney	1	0,15	5	3,10	1,30	0,39	4,70
Haematology other	10	1,53	7	4,34	1,27	0,49	4,52
Anus	2	0,31	3	1,86	1,03	0,21	4,47
Myeloma	1	0,15	3	1,86	0,95	0,19	4,36
Larynx	0	0,00	3	1,86	0,94	0,15	4,43
Stomach	8	1,23	4	2,48	0,92	0,24	4,22
Leukaemia	1	0,15	3	1,86	0,91	0,19	4,29
Naso-Oropharynx	4	0,61	5	3,10	0,84	0,25	4,07
Vagina	3	0,46	3	1,86	0,81	0,14	4,19
Oesophagus	3	0,46	3	1,86	0,78	0,16	4,10
Salivary gland	3	0,46	1	0,62	0,58	0,01	4,14
Liver & Bile duct	4	0,61	2	1,24	0,48	0,05	3,78
Connective tissue	1	0,15	1	0,62	0,37	0,01	3,72
Tongue	5	0,77	1	0,62	0,32	0,01	3,64
Gum	1	0,15	1	0,62	0,32	0,01	3,64
Mouth	7	1,07	1	0,62	0,27	0,01	3,57
Small intestine	1	0,15	1	0,62	0,20	0,00	3,48
Vulva	2	0,31	1	0,62	0,15	0,00	3,42
Ill defined	4	0,61	1	0,62	0,12	0,00	3,40
<b>All sites</b>	<b>641</b>	<b>98</b>	<b>456</b>	<b>283</b>	<b>130</b>	<b>84</b>	<b>263</b>

Asian Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	169	31,35	87	144,51	125,99	98,75	158,73
Squamous cell carcinoma of skin	123	22,82	79	131,22	104,24	81,22	132,39
Colorectal	40	7,42	60	99,66	77,01	57,84	101,28
Lung	32	5,94	25	41,53	35,84	22,53	54,76
Stomach	4	0,74	21	34,88	28,69	16,96	46,10
Bladder	16	2,97	18	29,90	25,57	14,39	42,58
Haematology other	13	2,41	15	24,92	23,82	12,39	41,58
Primary site unknown	9	1,67	12	19,93	16,29	7,94	30,51
Larynx	7	1,30	11	18,27	13,82	6,86	26,31
Bone	3	0,56	7	11,63	12,80	4,63	27,88
Testis	3	0,56	9	14,95	11,62	5,01	24,13
Non Hodgkin lymphoma	7	1,30	9	14,95	11,56	5,13	23,76
Kidney	5	0,93	9	14,95	11,46	5,22	23,35
Brain, CNS	7	1,30	7	11,63	11,20	3,95	25,11
Pancreas	9	1,67	8	13,29	10,16	4,36	21,68
Liver & Bile duct	5	0,93	5	8,31	7,76	2,11	20,19
Penis	0	0,00	4	6,64	6,76	1,52	19,05
Tongue	3	0,56	5	8,31	6,03	1,95	16,13
Other specified	7	1,30	5	8,31	5,85	1,88	15,82
Connective tissue	5	0,93	3	4,98	5,59	0,91	17,67
Breast	3	0,56	4	6,64	4,94	1,33	14,77
Leukaemia	4	0,74	4	6,64	4,72	1,27	14,36
Hodgkin lymphoma	1	0,19	2	3,32	4,48	0,44	16,42
Mouth	2	0,37	3	4,98	3,84	0,78	13,37
Naso-Oropharynx	5	0,93	3	4,98	3,81	0,78	13,28
Thyroid	2	0,37	3	4,98	2,99	0,62	11,75
Endocrine	0	0,00	2	3,32	2,79	0,34	12,06
Myeloma	3	0,56	2	3,32	2,57	0,31	11,61
Salivary gland	3	0,56	1	1,66	1,40	0,04	10,08
Lip	1	0,19	1	1,66	1,40	0,04	10,08
Oesophagus	5	0,93	1	1,66	1,39	0,04	10,06
Small intestine	1	0,19	1	1,66	1,24	0,03	9,72
Mesothelioma	1	0,19	1	1,66	1,24	0,03	9,72
<b>All sites</b>	<b>498</b>	<b>92</b>	<b>427</b>	<b>709</b>	<b>589</b>	<b>362</b>	<b>1026</b>

Black Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	151	25,29	151	8,51	13,59	11,35	16,11
Squamous cell carcinoma of skin	72	12,06	72	4,06	5,55	4,19	7,18
Lung	53	8,88	53	2,99	4,12	3,00	5,52
Colorectal	42	7,04	42	2,37	3,22	2,22	4,51
Oesophagus	24	4,02	24	1,35	2,13	1,28	3,29
Larynx	16	2,68	16	0,90	1,60	0,77	2,83
Primary site unknown	16	2,68	16	0,90	1,14	0,64	1,89
Stomach	12	2,01	12	0,68	1,08	0,46	2,07
Kaposi Sarcoma	21	3,52	21	1,18	1,03	0,61	1,67
Naso-Oropharynx	17	2,85	17	0,96	1,01	0,57	1,69
Haematology other	16	2,68	16	0,90	0,93	0,52	1,58
Pancreas	12	2,01	12	0,68	0,87	0,44	1,56
Mouth	11	1,84	11	0,62	0,79	0,38	1,46
Non Hodgkin lymphoma	12	2,01	12	0,68	0,74	0,37	1,34
Other specified	11	1,84	11	0,62	0,73	0,35	1,36
Liver & Bile duct	12	2,01	12	0,68	0,71	0,35	1,32
Penis	12	2,01	12	0,68	0,71	0,36	1,30
Bladder	9	1,51	9	0,51	0,67	0,30	1,30
Brain, CNS	8	1,34	8	0,45	0,49	0,20	1,02
Melanoma	6	1,01	6	0,34	0,45	0,16	1,00
Eye	6	1,01	6	0,34	0,39	0,14	0,89
Kidney	5	0,84	5	0,28	0,38	0,12	0,92
Anus	6	1,01	6	0,34	0,38	0,13	0,89
Tongue	5	0,84	5	0,28	0,36	0,11	0,89
Connective tissue	5	0,84	5	0,28	0,32	0,10	0,81
Ill defined	6	1,01	6	0,34	0,30	0,11	0,75
BCC	1	0,17	1	0,06	0,30	0,01	1,20
Myeloma	4	0,67	4	0,23	0,27	0,07	0,75
Testis	4	0,67	4	0,23	0,27	0,07	0,74
Thyroid	3	0,50	3	0,17	0,25	0,05	0,75
Bone	3	0,50	3	0,17	0,23	0,05	0,71
Hodgkin lymphoma	3	0,50	3	0,17	0,21	0,04	0,67
Breast	3	0,50	3	0,17	0,21	0,04	0,66
Endocrine	3	0,50	3	0,17	0,18	0,03	0,61
Small intestine	2	0,34	2	0,11	0,14	0,02	0,57
Salivary gland	2	0,34	2	0,11	0,13	0,01	0,55
Burkitt lymphoma	1	0,17	1	0,06	0,07	0,00	0,45
Mesothelioma	1	0,17	1	0,06	0,06	0,00	0,43
Lip	1	0,17	1	0,06	0,06	0,00	0,43
<b>All sites</b>	<b>597</b>	<b>100</b>	<b>597</b>	<b>34</b>	<b>46</b>	<b>30</b>	<b>74</b>

Coloured Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	4	13,33	4	2,16	3,09	0,60	8,37
Lung	6	20,00	6	3,25	3,02	1,10	6,84
Stomach	3	10,00	3	1,62	2,54	0,33	7,72
Mouth	1	3,33	1	0,54	1,62	0,04	6,73
Bone	1	3,33	1	0,54	1,62	0,04	6,73
Connective tissue	1	3,33	1	0,54	1,62	0,04	6,73
Primary site unknown	3	10,00	3	1,62	1,55	0,32	4,81
BCC	2	6,67	2	1,08	1,06	0,13	4,12
Colorectal	2	6,67	2	1,08	1,05	0,13	4,10
Squamous cell carcinoma of skin	2	6,67	2	1,08	1,04	0,13	4,08
Testis	1	3,33	1	0,54	0,61	0,02	3,51
Non Hodgkin lymphoma	1	3,33	1	0,54	0,53	0,01	3,29
Tongue	1	3,33	1	0,54	0,51	0,01	3,26
Oesophagus	1	3,33	1	0,54	0,49	0,01	3,19
Brain, CNS	1	3,33	1	0,54	0,44	0,01	3,09
<b>All sites</b>	<b>30</b>	<b>100</b>	<b>30</b>	<b>16</b>	<b>21</b>	<b>3</b>	<b>77</b>

White Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	87	20,37	169	107,24	41,47	35,13	49,26
Squamous cell carcinoma of skin	79	18,50	123	78,05	32,97	27,04	40,44
Colorectal	60	14,05	40	25,38	10,08	7,02	14,87
Lung	25	5,85	32	20,31	7,44	4,98	11,67
BCC	0	0,00	28	17,77	7,31	4,74	11,69
Haematology other	15	3,51	13	8,25	3,98	1,86	8,23
Bladder	18	4,22	16	10,15	3,60	1,98	7,19
Brain, CNS	7	1,64	7	4,44	2,50	0,88	6,41
Melanoma	0	0,00	8	5,08	2,47	1,05	6,05
Pancreas	8	1,87	9	5,71	2,19	0,95	5,61
Non Hodgkin lymphoma	9	2,11	7	4,44	2,10	0,79	5,67
Primary site unknown	12	2,81	9	5,71	2,10	0,92	5,46
Testis	9	2,11	3	1,90	1,95	0,32	6,36
Larynx	11	2,58	7	4,44	1,88	0,72	5,29
Connective tissue	3	0,70	5	3,17	1,88	0,55	5,59
Other specified	5	1,17	7	4,44	1,83	0,68	5,24
Naso-Oropharynx	3	0,70	5	3,17	1,77	0,55	5,34
Kidney	9	2,11	5	3,17	1,41	0,44	4,75
Leukaemia	4	0,94	4	2,54	1,27	0,28	4,75
Liver & Bile duct	5	1,17	5	3,17	1,22	0,36	4,48
Tongue	5	1,17	3	1,90	1,03	0,21	4,37
Oesophagus	1	0,23	5	3,17	1,01	0,31	4,17
Bone	7	1,64	3	1,90	0,94	0,19	4,23
Stomach	21	4,92	4	2,54	0,91	0,23	4,09
Ill defined	0	0,00	3	1,90	0,90	0,18	4,16
Breast	4	0,94	3	1,90	0,88	0,12	4,26
Myeloma	2	0,47	3	1,90	0,78	0,14	4,02
Salivary gland	1	0,23	3	1,90	0,71	0,13	3,90
Thyroid	3	0,70	2	1,27	0,66	0,05	4,02
Mouth	3	0,70	2	1,27	0,63	0,08	3,86
Eye	0	0,00	2	1,27	0,46	0,05	3,60
Hodgkin lymphoma	2	0,47	1	0,63	0,36	0,01	3,59
Small intestine	1	0,23	1	0,63	0,34	0,01	3,55
Mesothelioma	1	0,23	1	0,63	0,13	0,00	3,28
Lip	1	0,23	1	0,63	0,13	0,00	3,28
<b>All sites</b>	<b>421</b>	<b>99</b>	<b>539</b>	<b>342</b>	<b>141</b>	<b>93</b>	<b>273</b>

**Age-Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x**

ALL FEMALES																		
Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	2,70	1,73	2,80	4,44	6,86	18,37	38,23	78,64	119,59	191,36	226,29	321,05	425,33	491,26	659,50	670,90	1648,09	8
All sites but C44	2,70	1,73	2,80	4,44	5,14	17,35	34,93	71,89	104,49	168,21	199,50	274,13	360,71	415,69	566,42	527,78	1277,87	9
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,47	1,45	2,42	2,31	1,85	3,70	4,51	0,00	0,00	8,95	0,00	1197
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,47	0,96	0,00	1,54	0,92	1,23	3,01	5,97	2,66	13,42	47,77	1194
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,81	0,77	1,85	0,00	3,01	5,97	0,00	4,47	23,89	1492
Bone	0,00	0,00	0,00	0,55	0,57	0,51	0,00	0,48	0,00	0,77	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6945
Brain, CNS	0,00	0,58	0,00	0,00	0,00	0,00	0,47	0,96	2,42	1,54	4,62	3,70	4,51	7,96	5,32	4,47	23,89	624
Breast	0,00	0,00	0,00	0,55	1,71	3,06	7,08	19,78	32,61	45,52	63,73	106,19	124,74	157,13	188,81	201,27	453,82	27
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	41667
Cervix	0,00	0,00	0,00	0,00	0,00	3,06	10,38	21,71	25,97	52,47	41,56	56,80	46,59	47,73	58,50	8,95	107,48	55
Colorectal	0,00	0,00	0,56	0,55	1,14	0,00	0,94	2,89	4,83	4,63	10,16	12,35	34,57	33,81	39,89	49,20	191,08	137
Connective tissue	0,54	0,00	0,00	0,00	0,00	0,00	0,47	0,00	1,21	1,54	0,92	1,23	0,00	1,99	0,00	4,47	11,94	2532
Endocrine	0,54	0,00	0,00	0,55	0,00	1,02	0,00	0,48	0,60	0,00	0,92	1,23	0,00	1,99	2,66	0,00	0,00	2003
Eye	0,54	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,77	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10472
Gum	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,23	0,00	0,00	0,00	0,00	11,94	16261
Haematology other	0,00	0,00	0,00	0,00	0,57	0,51	0,47	1,45	3,02	1,54	0,92	1,23	6,01	5,97	18,61	13,42	35,83	497
Hodgkin lymphoma	0,00	0,00	0,56	0,00	0,00	1,02	0,94	0,48	0,00	0,77	0,00	3,70	0,00	0,00	0,00	0,00	0,00	2678
Ill defined	0,00	0,58	0,00	0,00	0,00	0,51	0,94	0,96	1,21	0,00	0,00	1,23	3,01	1,99	2,66	8,95	0,00	1528
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,02	1,42	2,41	0,60	2,31	0,92	0,00	1,50	0,00	0,00	0,00	0,00	1965
Kidney	0,00	0,58	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,77	0,92	1,23	0,00	1,99	2,66	4,47	11,94	2286
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,00	0,77	0,00	0,00	1,50	0,00	0,00	4,47	0,00	7273
Leukaemia	0,00	0,00	1,12	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,23	1,50	1,99	0,00	0,00	23,89	3425
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	33334

Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,45	2,42	1,54	4,62	1,23	6,01	1,99	2,66	0,00	23,89	913
Lung	0,00	0,00	0,00	0,00	0,00	0,51	1,42	0,00	0,00	1,54	3,69	4,94	10,52	13,92	37,23	17,89	59,71	272
Melanoma	0,00	0,00	0,00	0,00	1,14	0,00	0,00	0,48	0,00	0,77	0,92	0,00	3,01	0,00	13,30	8,95	11,94	1020
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,50	0,00	2,66	0,00	0,00	4808
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,77	0,92	2,47	1,50	7,96	7,98	0,00	0,00	926
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,00	0,92	1,23	1,50	1,99	2,66	4,47	0,00	2248
Naso-Oropharynx	0,00	0,00	0,56	0,00	0,00	1,53	1,89	0,96	0,00	1,54	0,92	1,23	3,01	1,99	5,32	8,95	23,89	1056
Non Hodgkin lymphoma	0,00	0,00	0,00	0,55	0,00	0,51	0,47	1,45	1,81	5,40	1,85	0,00	1,50	5,97	2,66	8,95	0,00	903
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,00	0,77	5,54	7,41	10,52	17,90	18,61	22,36	35,83	327
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,60	2,31	2,77	6,17	4,51	0,00	5,32	4,47	23,89	903
Ovary	0,00	0,00	0,00	1,11	0,00	0,51	1,89	0,96	2,42	3,86	8,31	9,88	7,51	11,93	23,93	4,47	11,94	277
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,77	2,77	1,23	3,01	5,97	5,32	22,36	23,89	1049
Placenta	0,00	0,00	0,00	0,00	0,00	0,00	0,94	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	21277
Primary site unknown	1,08	0,00	0,00	0,00	0,00	1,02	0,00	0,96	0,00	3,09	4,62	7,41	4,51	7,96	2,66	22,36	47,77	601
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,51	0,47	1,45	0,00	0,77	0,00	0,00	1,50	0,00	0,00	0,00	0,00	4256
Skin other	0,00	0,00	0,00	0,55	1,71	2,04	2,83	7,24	15,70	23,92	35,10	51,86	70,64	83,53	109,03	134,18	346,34	50
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,00	0,92	0,00	0,00	0,00	5,32	0,00	0,00	2924
Stomach	0,00	0,00	0,00	0,00	0,00	0,51	0,00	0,48	0,60	0,77	2,77	2,47	7,51	7,96	10,64	4,47	0,00	594
Thyroid	0,00	0,00	0,00	0,00	0,00	0,51	1,89	1,45	1,81	3,86	3,69	2,47	1,50	3,98	5,32	0,00	0,00	756
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,96	0,00	0,77	0,00	1,23	4,51	0,00	5,32	4,47	0,00	1564
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,47	0,00	1,21	6,17	3,69	13,58	37,57	37,79	55,84	62,62	59,71	128
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,47	0,00	0,60	0,00	2,77	2,47	4,51	3,98	7,98	4,47	11,94	878
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	1,42	4,82	12,68	14,66	10,16	7,41	4,51	1,99	7,98	8,95	23,89	305

ASIAN FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	33,94	34,44	96,38	126,90	279,64	527,49	822,08	1240,04	1586,79	2322,88	2659,02	3313,66	4308,27	3385,54	3665,78	2
All sites but C44	0,00	0,00	33,94	34,44	64,25	101,52	258,13	486,91	641,62	1085,04	1322,32	1944,74	1964,05	2673,52	3839,98	2938,39	2777,10	2
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	24,04	27,01	0,00	0,00	0,00	0,00	0,00	392
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	75,31	0,00	63,88	111,08	266
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,29	20,05	0,00	0,00	27,01	30,22	112,97	0,00	63,88	0,00	95
Breast	0,00	0,00	0,00	0,00	32,13	50,76	64,53	202,88	340,86	398,58	673,18	1080,41	815,84	1280,28	1639,02	1277,56	1110,84	4
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	0,00	60,86	80,20	110,72	48,08	135,05	120,86	75,31	140,49	0,00	111,08	26
Colorectal	0,00	0,00	33,94	0,00	32,13	0,00	21,51	20,29	60,15	44,29	96,17	108,04	302,16	263,59	374,63	383,27	777,59	15
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	111,08	
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	24,04	0,00	0,00	37,66	0,00	0,00	0,00	325
Gum	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	111,08	
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,29	20,05	0,00	0,00	0,00	30,22	37,66	187,32	127,76	0,00	68
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	54,02	0,00	0,00	0,00	0,00	0,00	371
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	21,51	20,29	0,00	0,00	0,00	0,00	0,00	37,66	46,83	0,00	0,00	159
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	63,88	0,00	
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	111,08	
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,14	24,04	0,00	30,22	0,00	46,83	0,00	0,00	163
Lung	0,00	0,00	0,00	0,00	0,00	0,00	43,02	0,00	0,00	22,14	0,00	81,03	60,43	75,31	234,15	191,63	0,00	39
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,22	0,00	46,83	0,00	0,00	260
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,14	24,04	27,01	30,22	37,66	93,66	0,00	0,00	86
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	63,88	0,00	
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,29	0,00	22,14	24,04	0,00	30,22	0,00	0,00	0,00	0,00	207
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	88,57	0,00	0,00	30,22	75,31	0,00	0,00	0,00	104
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	75,31	0,00	63,88	0,00	266
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,14	72,13	54,02	30,22	0,00	0,00	0,00	111,08	113
Ovary	0,00	0,00	0,00	34,44	0,00	0,00	64,53	20,29	40,10	88,57	24,04	108,04	30,22	75,31	140,49	0,00	0,00	32

Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	48,08	0,00	30,22	0,00	46,83	127,76	0,00	160
Placenta	0,00	0,00	0,00	0,00	0,00	0,00	21,51	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	930
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,14	48,08	54,02	30,22	75,31	0,00	63,88	111,08	88
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	40,58	0,00	0,00	0,00	0,00	30,22	0,00	0,00	0,00	0,00	283
Squamous cell carcinoma of skin	0,00	0,00	0,00	0,00	32,13	76,14	21,51	40,58	200,51	221,44	336,59	405,15	725,19	715,45	468,29	447,15	888,67	7
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	24,04	0,00	0,00	0,00	0,00	0,00	0,00	832
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,29	0,00	22,14	24,04	27,01	30,22	37,66	46,83	63,88	0,00	97
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	21,51	40,58	40,10	66,43	48,08	27,01	30,22	0,00	46,83	0,00	0,00	63
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	60,43	0,00	93,66	63,88	0,00	130
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,05	66,43	24,04	108,04	151,08	188,28	515,12	255,51	111,08	19
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,66	93,66	0,00	0,00	153
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	46,83	63,88	0,00	428

BLACK FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	3,17	2,08	2,73	4,80	5,87	18,89	36,99	72,06	108,81	156,15	155,21	184,69	201,75	187,98	228,84	190,93	488,28	15
All sites but C44	3,17	2,08	2,73	4,80	4,40	18,24	34,00	65,29	98,16	138,80	141,87	155,60	186,87	175,01	192,71	158,33	412,33	17
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,60	1,85	3,04	2,89	0,00	2,91	0,00	0,00	0,00	9,31	0,00	1772
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,60	1,23	0,00	1,93	0,00	1,45	0,00	0,00	0,00	4,66	0,00	3839
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,28	0,96	2,43	0,00	3,31	2,16	0,00	0,00	10,85	1796
Bone	0,00	0,00	0,00	0,69	0,73	0,65	0,00	0,62	0,00	0,96	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5480
Brain, CNS	0,00	0,69	0,00	0,00	0,00	0,00	0,60	0,62	2,28	0,00	2,43	1,45	1,65	0,00	6,02	0,00	10,85	1271
Breast	0,00	0,00	0,00	0,69	1,47	2,61	7,16	12,32	21,31	27,95	25,46	43,63	44,65	47,53	36,13	51,22	108,51	74
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32259
Cervix	0,00	0,00	0,00	0,00	0,00	3,91	11,33	25,87	29,68	59,76	52,14	52,35	41,34	47,53	51,19	9,31	75,95	54
Colorectal	0,00	0,00	0,00	0,69	0,73	0,00	0,60	2,46	2,28	1,93	3,64	4,36	11,58	6,48	6,02	0,00	43,40	491
Connective tissue	0,63	0,00	0,00	0,00	0,00	0,00	0,60	0,00	1,52	1,93	0,00	1,45	0,00	2,16	0,00	4,66	0,00	2413
Endocrine	0,63	0,00	0,00	0,69	0,00	1,30	0,00	0,62	0,76	0,00	0,00	1,45	0,00	0,00	3,01	0,00	0,00	2365
Eye	0,63	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,96	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8511
Haematology other	0,00	0,00	0,00	0,00	0,73	0,65	0,60	1,23	3,04	1,93	1,21	1,45	4,96	2,16	0,00	0,00	0,00	1114
Hodgkin lymphoma	0,00	0,00	0,68	0,00	0,00	1,30	1,19	0,62	0,00	0,96	0,00	1,45	0,00	0,00	0,00	0,00	0,00	3226
Ill defined	0,00	0,69	0,00	0,00	0,00	0,65	0,60	0,62	1,52	0,00	0,00	1,45	3,31	0,00	0,00	4,66	0,00	2263
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,30	1,79	3,08	0,76	2,89	1,21	0,00	1,65	0,00	0,00	0,00	0,00	1578
Kidney	0,00	0,69	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,96	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8299
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32259
Leukaemia	0,00	0,00	1,36	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,85	14706
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26316
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,85	3,04	0,96	4,85	1,45	3,31	2,16	0,00	0,00	10,85	1136
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,00	0,00	0,96	3,64	1,45	6,61	4,32	9,03	0,00	21,70	752
Melanoma	0,00	0,00	0,00	0,00	0,73	0,00	0,00	0,62	0,00	0,96	1,21	0,00	0,00	0,00	6,02	9,31	10,85	2097
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,45	0,00	4,32	3,01	0,00	0,00	2278

Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,00	0,00	1,65	0,00	3,01	0,00	0,00	3691
Naso-Oropharynx	0,00	0,00	0,68	0,00	0,00	1,95	2,39	0,62	0,00	0,96	0,00	1,45	1,65	0,00	3,01	0,00	10,85	1574
Non Hodgkin lymphoma	0,00	0,00	0,00	0,69	0,00	0,65	0,60	0,62	2,28	1,93	1,21	0,00	0,00	0,00	0,00	9,31	0,00	2507
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,96	7,28	7,27	11,58	12,96	18,07	18,63	32,55	341
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,62	0,76	0,96	0,00	1,45	3,31	0,00	3,01	0,00	0,00	1979
Ovary	0,00	0,00	0,00	0,69	0,00	0,65	0,60	0,62	1,52	0,00	8,49	4,36	6,61	4,32	3,01	0,00	10,85	648
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,45	0,00	0,00	0,00	0,00	0,00	13794
Placenta	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	33334
Primary site unknown	1,27	0,00	0,00	0,00	0,00	1,30	0,00	0,62	0,00	2,89	3,64	2,91	1,65	2,16	0,00	4,66	0,00	1217
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,65	0,60	0,00	0,00	0,96	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9050
Squamous cell carcinoma of skin	0,00	0,00	0,00	0,69	1,47	0,65	2,39	6,77	10,65	15,42	16,98	29,08	14,88	19,45	39,14	32,60	75,95	127
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,00	0,00	0,00	0,00	3,01	0,00	0,00	5306
Stomach	0,00	0,00	0,00	0,00	0,00	0,65	0,00	0,00	0,76	0,00	2,43	0,00	4,96	6,48	0,00	0,00	0,00	1309
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	1,19	0,00	0,76	0,96	0,00	1,45	0,00	2,16	0,00	0,00	0,00	3068
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,96	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12659
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,89	1,21	7,27	24,81	17,29	27,10	27,94	32,55	249
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,60	0,00	0,76	0,00	2,43	2,91	3,31	2,16	3,01	0,00	10,85	1318
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	1,79	6,16	15,98	18,31	13,34	7,27	4,96	2,16	6,02	4,66	10,85	264

**COLOURED FEMALES**

Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	0,00	0,00	6,60	6,60	27,67	22,60	25,61	41,67	43,06	121,44	108,02	132,24	60,15	295,51	38
All sites but C44	0,00	0,00	0,00	0,00	0,00	6,60	6,60	27,67	22,60	25,61	33,34	43,06	101,20	108,02	113,35	60,15	177,30	41
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,12	0,00	0,00	0,00	0,00	1977
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,12	0,00	0,00	0,00	59,10	1977
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,76	15,07	25,61	16,67	8,61	40,48	54,01	56,68	0,00	59,10	85
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	6,60	0,00	0,00	0,00	0,00	8,61	10,12	0,00	37,78	0,00	59,10	317
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,53	0,00	0,00	8,61	10,12	40,51	0,00	0,00	0,00	300
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	59,10	
Lung	0,00	0,00	0,00	0,00	0,00	6,60	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3031
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,07	0,00	
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,67	0,00	20,24	0,00	18,89	0,00	59,10	359
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,61	0,00	0,00	0,00	0,00	0,00	2323
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,33	0,00	0,00	0,00	0,00	0,00	0,00	2401
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,92	0,00	0,00	0,00	0,00	10,12	0,00	0,00	0,00	0,00	1174
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,12	13,50	18,89	30,07	0,00	471
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,61	0,00	0,00	0,00	0,00	0,00	2323

WHITE FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	0,00	12,51	11,36	53,75	153,87	100,71	224,56	337,60	332,78	502,13	572,35	719,28	626,27	812,22	7
All sites but C44	0,00	0,00	0,00	0,00	12,51	11,36	43,00	144,25	82,40	182,98	293,57	301,08	428,05	438,20	601,04	417,52	605,47	8
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,34	0,00	16,46	0,00	0,00	0,00	0,00	841
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,34	0,00	8,23	26,83	9,85	23,20	44,30	383
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,63	22,02	7,92	8,23	8,94	0,00	0,00	14,77	314
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	76,93	64,09	74,85	132,11	118,85	205,79	169,92	206,92	162,37	251,05	20
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	21,50	0,00	0,00	8,32	0,00	31,69	8,23	0,00	0,00	0,00	0,00	287
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,62	9,16	16,63	29,36	15,85	41,16	35,77	49,27	57,99	73,84	97
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,34	0,00	0,00	0,00	0,00	0,00	0,00	2725
Gum	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,92	0,00	0,00	0,00	0,00	0,00	2526
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,94	29,56	11,60	29,54	520
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,60	0,00	
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,34	7,92	0,00	8,94	9,85	0,00	14,77	588
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,32	0,00	0,00	8,23	0,00	0,00	11,60	0,00	1209
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,92	8,23	8,94	0,00	0,00	0,00	798
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,23	0,00	0,00	0,00	14,77	2431
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,34	0,00	8,23	26,83	59,12	11,60	44,30	198
Melanoma	0,00	0,00	0,00	0,00	12,51	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,46	0,00	29,56	0,00	0,00	342
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,94	0,00	0,00	0,00	2238
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,34	7,92	0,00	8,94	0,00	0,00	0,00	827
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,94	9,85	23,20	14,77	1065
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,23	0,00	8,32	7,34	0,00	0,00	8,94	9,85	0,00	0,00	373
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,92	0,00	8,94	9,85	0,00	0,00	749
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,32	0,00	15,85	0,00	0,00	9,85	11,60	14,77	588
Ovary	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,32	7,34	7,92	0,00	17,89	49,27	11,60	0,00	221

Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,32	7,34	0,00	8,23	26,83	9,85	23,20	29,54	331
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,62	0,00	0,00	0,00	15,85	8,23	8,94	9,85	34,79	44,30	382
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,62	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2080
Squamous cell carcinoma of skin	0,00	0,00	0,00	0,00	0,00	0,00	10,75	19,23	18,31	41,59	58,71	55,46	98,78	125,20	167,50	185,56	191,98	34
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,85	0,00	0,00	2031
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,23	0,00	29,56	0,00	0,00	530
Thyroid	0,00	0,00	0,00	0,00	0,00	11,36	10,75	9,62	0,00	8,32	7,34	0,00	0,00	8,94	9,85	0,00	0,00	303
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,92	0,00	0,00	0,00	0,00	0,00	2526
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	10,75	0,00	9,16	16,63	14,68	15,85	32,93	44,71	0,00	34,79	14,77	139
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,34	0,00	8,23	0,00	0,00	11,60	0,00	1285
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,77	

ALL MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	2,25	3,02	1,76	7,04	7,44	5,51	12,71	18,74	36,11	68,94	109,58	195,45	263,37	368,75	407,58	574,49	764,27	14
All sites but C44	2,25	3,02	1,76	6,45	7,44	3,86	11,69	17,17	28,02	57,58	93,54	156,15	216,76	305,07	328,82	437,30	548,98	17
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,52	0,62	0,00	0,89	2,07	0,00	1,48	0,00	0,00	0,00	3585
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,00	2,07	4,66	7,40	11,81	14,29	43,06	750
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,25	1,52	6,24	1,03	3,50	5,92	21,66	22,87	26,91	487
Bone	0,00	0,00	0,00	0,00	0,62	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4,66	5,92	0,00	5,72	16,15	1786
Brain, CNS	0,00	0,60	0,59	0,59	0,62	0,55	0,51	1,04	1,87	0,76	2,67	2,07	1,17	1,48	1,97	2,86	10,76	1213
Breast	0,00	0,00	0,00	0,00	0,62	0,00	0,00	0,52	0,00	0,76	0,89	0,00	2,33	1,48	1,97	5,72	0,00	2334
Burkitt lymphoma	0,00	0,60	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	33334
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,60	4,36	10,61	12,47	20,68	17,48	31,10	39,38	54,31	48,44	145
Connective tissue	0,56	0,60	0,00	0,00	0,00	0,55	0,00	0,52	1,25	0,00	0,89	1,03	1,17	1,48	3,94	0,00	10,76	1669
Endocrine	0,00	0,00	0,00	0,59	0,00	0,00	0,51	0,00	0,00	0,00	0,00	0,00	1,17	1,48	0,00	2,86	0,00	5334
Eye	0,56	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	3,56	0,00	0,00	0,00	1,97	0,00	5,38	2920
Haematology other	0,00	0,00	0,00	0,59	0,62	0,55	1,02	1,04	1,87	3,03	3,56	3,10	2,33	14,81	5,91	11,43	21,53	521
Hodgkin lymphoma	0,00	0,00	0,00	0,59	0,00	0,00	0,00	0,00	0,00	0,00	0,89	0,00	2,33	1,48	0,00	0,00	5,38	3781
Ill defined	0,00	0,00	0,59	0,00	0,62	0,00	1,02	0,00	0,00	0,76	0,89	0,00	1,17	1,48	0,00	0,00	5,38	3063
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	3,05	2,60	1,87	0,00	0,89	4,14	1,17	0,00	0,00	2,86	0,00	1458
Kidney	1,13	0,00	0,59	0,00	0,00	0,00	0,00	0,00	0,00	1,52	0,00	1,03	5,83	2,96	7,88	5,72	0,00	956
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,52	0,62	1,52	2,67	4,14	12,82	5,92	0,00	8,57	26,91	709
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	1,02	0,00	0,00	0,00	0,00	1,03	1,17	0,00	5,91	0,00	5,38	2191
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,00	0,00	1,48	0,00	2,86	0,00	8929
Liver & Bile duct	0,00	0,00	0,00	0,00	0,62	0,00	0,51	1,04	1,25	0,76	2,67	2,07	1,17	2,96	7,88	5,72	5,38	956
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,51	1,04	1,25	6,82	8,02	15,51	26,80	29,62	31,50	31,44	43,06	166
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,89	4,14	4,66	2,96	0,00	0,00	10,76	1492
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,00	0,00	0,00	1,97	2,86	0,00	7327
Mouth	0,00	0,60	0,00	0,00	0,00	0,00	0,51	0,52	0,00	0,00	1,78	2,07	5,83	4,44	0,00	2,86	5,38	1270

Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,27	0,89	0,00	3,50	1,48	0,00	2,86	0,00	2458
Naso-Oropharynx	0,00	0,00	0,00	0,59	0,00	0,55	1,02	1,56	0,62	1,52	2,67	4,14	1,17	7,40	1,97	2,86	0,00	862
Non Hodgkin lymphoma	0,00	0,00	0,00	0,59	1,86	0,00	0,51	0,52	1,25	0,76	4,45	3,10	3,50	4,44	3,94	5,72	10,76	803
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,89	9,31	12,82	2,96	5,91	5,72	10,76	616
Other specified	0,00	0,00	0,00	0,00	0,00	0,55	0,00	0,52	0,62	0,76	1,78	4,14	3,50	4,44	5,91	11,43	0,00	901
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,62	5,30	0,00	3,10	9,32	5,92	3,94	5,72	10,76	710
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,52	1,25	2,27	4,45	3,10	1,17	0,00	0,00	0,00	5,38	1568
Primary site unknown	0,00	0,00	0,00	0,59	0,62	0,00	0,00	0,00	0,62	3,79	4,45	4,14	5,83	5,92	5,91	11,43	37,68	628
Prostate	0,00	0,00	0,00	0,00	0,00	0,55	0,00	0,00	0,00	6,06	17,82	50,67	69,92	133,28	149,64	202,93	193,76	47
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,51	0,00	0,00	0,00	0,00	0,00	0,00	5,92	0,00	2,86	0,00	3111
Squamous cell carcinoma of skin	0,00	0,00	0,00	0,59	0,00	1,65	0,00	2,60	8,09	10,61	17,82	37,23	43,12	56,27	68,91	120,04	172,23	82
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,10	0,00	0,00	1,97	0,00	0,00	3945
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,04	3,11	0,00	2,67	4,14	2,33	11,85	11,81	11,43	32,29	542
Testis	0,00	0,60	0,00	2,35	1,24	0,55	2,03	0,00	1,25	0,76	0,00	0,00	1,17	0,00	0,00	2,86	0,00	2011
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,87	0,76	0,00	1,03	1,17	0,00	1,97	2,86	0,00	2942
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,27	1,78	2,07	3,50	2,96	1,97	2,86	0,00	1375

ASIAN MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	31,51	31,17	78,82	38,34	81,13	110,28	249,09	490,15	864,34	1392,09	2610,54	2570,19	3343,77	6289,11	10781,01	2
All sites but C44	0,00	0,00	31,51	31,17	78,82	38,34	81,13	78,77	232,48	392,12	731,37	1169,36	2088,43	2196,35	2786,48	4507,19	9240,86	3
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,61	19,61	88,65	0,00	69,61	140,19	185,77	209,64	616,06	39
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	69,61	93,46	0,00	104,82	616,06	123
Brain, CNS	0,00	0,00	31,51	31,17	0,00	0,00	0,00	15,75	16,61	0,00	22,16	27,84	34,81	0,00	0,00	0,00	0,00	112
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,16	0,00	69,61	0,00	0,00	104,82	0,00	218
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	15,75	49,82	137,24	177,30	278,42	208,84	327,12	557,30	628,91	924,09	12
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27,84	34,81	0,00	0,00	0,00	308,03	320
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34,81	46,73	0,00	0,00	0,00	246
Haematology other	0,00	0,00	0,00	0,00	0,00	19,17	0,00	15,75	0,00	19,61	44,33	55,68	34,81	93,46	61,92	104,82	924,09	59
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	46,73	0,00	0,00	308,03	428
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	39,21	0,00	0,00	104,42	46,73	123,84	104,82	0,00	64
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	83,53	104,42	140,19	0,00	209,64	0,00	61
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	16,23	0,00	0,00	0,00	0,00	27,84	34,81	0,00	61,92	0,00	0,00	143
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	46,73	0,00	0,00	0,00	428
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,61	0,00	0,00	0,00	34,81	0,00	61,92	104,82	308,03	177
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	66,49	55,68	278,46	280,38	123,84	209,64	616,06	25
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	61,92	0,00	0,00	323
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34,81	46,73	0,00	104,82	0,00	246
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,61	0,00	0,00	34,81	0,00	0,00	0,00	0,00	368
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,61	0,00	0,00	34,81	0,00	61,92	0,00	0,00	172
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	26,27	0,00	0,00	15,75	0,00	0,00	22,16	27,84	34,81	93,46	0,00	209,64	0,00	91
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34,81	0,00	0,00	0,00	0,00	575
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27,84	0,00	46,73	61,92	209,64	0,00	147

Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	39,21	0,00	55,68	104,42	46,73	0,00	0,00	0,00	82
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,61	22,16	0,00	34,81	0,00	0,00	0,00	308,03	262
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,61	66,49	55,68	34,81	93,46	61,92	104,82	308,03	61
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	39,21	155,14	306,26	487,30	420,58	990,75	1781,91	3388,32	9
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	46,73	0,00	0,00	0,00	428
Squamous cell carcinoma of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	47,26	16,61	98,03	155,14	222,73	556,91	373,85	557,30	1781,91	1540,14	10
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	61,92	0,00	0,00	323
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	49,82	0,00	22,16	83,53	69,61	140,19	247,69	314,46	616,06	33
Testis	0,00	0,00	0,00	0,00	52,55	19,17	64,91	0,00	33,21	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	118
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	49,82	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	402
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,61	0,00	55,68	34,81	0,00	61,92	0,00	0,00	117

BLACK MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	2,44	3,30	1,30	5,85	4,75	4,85	10,04	14,35	25,88	57,12	85,97	174,12	177,87	301,33	202,37	219,69	389,63	19
All sites but C44	2,44	3,30	1,30	5,20	4,75	3,03	8,93	13,78	19,97	49,24	77,12	134,63	168,86	260,95	193,57	202,79	299,72	22
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,57	0,74	0,00	1,26	3,59	0,00	3,11	0,00	0,00	0,00	2158
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29,97	
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,98	2,53	0,00	0,00	3,11	8,80	16,90	0,00	1238
Bone	0,00	0,00	0,00	0,00	0,68	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,25	0,00	0,00	8,45	0,00	6826
Brain, CNS	0,00	0,66	0,00	0,00	0,68	0,61	0,00	0,00	1,48	0,00	1,26	1,80	0,00	3,11	0,00	0,00	0,00	2084
Breast	0,00	0,00	0,00	0,00	0,68	0,00	0,00	0,00	0,00	0,98	0,00	0,00	0,00	3,11	0,00	0,00	0,00	4193
Burkitt lymphoma	0,00	0,66	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30304
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,30	2,22	5,91	6,32	8,98	9,01	24,85	13,20	25,35	29,97	275
Connective tissue	0,61	0,66	0,00	0,00	0,00	0,61	0,00	0,57	0,00	0,00	0,00	0,00	0,00	3,11	0,00	0,00	0,00	3598
Endocrine	0,00	0,00	0,00	0,65	0,00	0,00	0,56	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,45	0,00	16529
Eye	0,61	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,98	5,06	0,00	0,00	0,00	0,00	0,00	0,00	3008
Haematology other	0,00	0,00	0,00	0,65	0,00	0,00	1,12	0,57	2,22	2,95	2,53	1,80	2,25	0,00	4,40	8,45	0,00	1082
Hodgkin lymphoma	0,00	0,00	0,00	0,65	0,00	0,00	0,00	0,00	0,00	0,00	1,26	0,00	2,25	0,00	0,00	0,00	0,00	4808
Ill defined	0,00	0,00	0,65	0,00	0,68	0,00	1,12	0,00	0,00	0,98	1,26	0,00	0,00	0,00	0,00	0,00	0,00	4265
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	3,35	2,87	2,22	0,00	1,26	7,18	2,25	0,00	0,00	8,45	0,00	1046
Kidney	1,22	0,00	0,65	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,25	0,00	0,00	8,45	0,00	4855
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,57	0,74	1,97	3,79	1,80	13,51	0,00	0,00	0,00	59,94	894
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,98	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20409

Liver & Bile duct	0,00	0,00	0,00	0,00	0,68	0,00	0,56	1,15	0,74	0,98	2,53	3,59	0,00	3,11	4,40	0,00	0,00	1128
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,56	1,15	1,48	8,86	7,59	16,16	27,02	15,53	26,40	0,00	29,97	191
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,98	1,26	3,59	4,50	0,00	0,00	0,00	0,00	1937
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,98	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20409
Mouth	0,00	0,66	0,00	0,00	0,00	0,00	0,56	0,57	0,00	0,00	2,53	1,80	9,01	3,11	0,00	0,00	0,00	1097
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,97	1,26	0,00	2,25	0,00	0,00	0,00	0,00	3650
Naso-Oropharynx	0,00	0,00	0,00	0,65	0,00	0,61	1,12	1,72	0,74	0,00	2,53	7,18	0,00	6,21	0,00	8,45	0,00	964
Non Hodgkin lymphoma	0,00	0,00	0,00	0,65	0,68	0,00	0,56	0,00	0,74	0,98	5,06	3,59	2,25	0,00	0,00	0,00	0,00	1379
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,00	1,26	16,16	20,26	3,11	8,80	0,00	29,97	398
Other specified	0,00	0,00	0,00	0,00	0,00	0,61	0,00	0,57	0,74	0,98	2,53	3,59	2,25	3,11	4,40	0,00	0,00	1065
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,74	4,92	0,00	1,80	6,75	6,21	0,00	0,00	0,00	980
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,57	1,48	1,97	5,06	5,39	0,00	0,00	0,00	0,00	0,00	1383
Primary site unknown	0,00	0,00	0,00	0,65	0,68	0,00	0,00	0,00	0,74	3,94	1,26	3,59	6,75	6,21	0,00	8,45	0,00	840
Prostate	0,00	0,00	0,00	0,00	0,00	0,61	0,00	0,00	0,00	5,91	13,91	35,90	49,53	155,33	114,38	92,95	119,89	54
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,00	0,00	0,00	0,00	3,11	0,00	0,00	0,00	5450
Skin other	0,00	0,00	0,00	0,65	0,00	1,82	0,00	0,57	5,92	6,89	8,85	39,49	9,01	40,39	8,80	16,90	59,94	164
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,59	0,00	0,00	0,00	0,00	0,00	5572
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,57	1,48	0,00	2,53	1,80	0,00	12,43	4,40	0,00	29,97	862
Testis	0,00	0,66	0,00	1,30	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,45	0,00	10205
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,80	2,25	0,00	4,40	0,00	0,00	2367
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,97	1,26	0,00	2,25	3,11	0,00	0,00	0,00	2329

COLOURED MALE																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	6,77	6,59	0,00	0,00	6,42	0,00	8,69	8,84	20,45	36,56	53,10	264,44	102,56	810,80	49
All sites but C44	0,00	0,00	0,00	6,77	6,59	0,00	0,00	6,42	0,00	8,69	8,84	20,45	36,56	53,10	185,11	51,28	810,80	61
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	52,89	0,00	0,00	379
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	162,16	
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,84	0,00	0,00	0,00	0,00	0,00	0,00	2263
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,69	0,00	0,00	0,00	17,70	0,00	0,00	0,00	758
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	162,16	
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,22	12,19	35,40	52,89	0,00	0,00	181
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	162,16	
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	6,59	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3035
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,19	0,00	0,00	0,00	0,00	1641
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,19	0,00	52,89	0,00	0,00	308
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,22	0,00	0,00	52,89	0,00	162,16	317
Squamous cell carcinoma of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26,44	51,28	0,00	757
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,42	0,00	0,00	0,00	0,00	0,00	0,00	26,44	0,00	162,16	609
Testis	0,00	0,00	0,00	6,77	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2955
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	51,28	0,00	

WHITE MALE																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	11,79	11,63	0,00	20,08	26,96	72,00	61,14	112,41	336,06	624,87	912,73	1023,54	1483,10	2173,10	7
All sites but C44	0,00	0,00	0,00	11,79	11,63	0,00	20,08	26,96	36,00	43,67	74,94	268,84	434,69	699,11	749,19	1115,61	1391,76	9
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,73	0,00	16,80	36,22	48,55	42,21	65,62	170,92	132
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,49	8,40	9,06	0,00	63,31	52,50	73,25	227
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,06	19,42	0,00	0,00	0,00	703
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	10,04	8,99	0,00	8,73	0,00	0,00	0,00	0,00	10,55	13,12	48,83	523
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,99	0,00	0,00	0,00	0,00	0,00	0,00	10,55	13,12	0,00	1024
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,00	0,00	7,49	42,01	45,28	48,55	84,42	131,25	122,08	85
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,00	0,00	7,49	0,00	0,00	0,00	21,10	0,00	0,00	430
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,55	0,00	24,42	1896
Haematology other	0,00	0,00	0,00	0,00	11,63	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	77,68	10,55	26,25	24,42	201
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,06	0,00	0,00	0,00	0,00	2208
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,06	9,71	0,00	0,00	24,42	1066
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,40	9,06	9,71	21,10	0,00	0,00	415
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,11	9,71	0,00	13,12	73,25	719
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	10,04	0,00	0,00	0,00	0,00	0,00	0,00	0,00	21,10	0,00	24,42	643
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,12	0,00	
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,49	0,00	0,00	9,71	21,10	13,12	0,00	523
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	25,20	18,11	67,97	63,31	118,12	122,08	115
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,80	18,11	19,42	0,00	0,00	48,83	369
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,12	0,00	
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,40	0,00	9,71	0,00	0,00	0,00	1105
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,06	9,71	0,00	13,12	0,00	1066
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,73	7,49	0,00	0,00	29,13	0,00	0,00	0,00	442
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,00	0,00	0,00	0,00	9,06	9,71	21,10	0,00	48,83	410
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,71	10,55	26,25	24,42	988

Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,40	18,11	9,71	10,55	26,25	0,00	428
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,11	9,71	21,10	26,25	48,83	409
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,49	0,00	0,00	0,00	0,00	26,25	146,50	2671
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,99	142,82	217,35	301,01	337,66	564,37	488,34	20
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,42	0,00	13,12	0,00	1030
Squamous cell carcinoma of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,99	36,00	17,47	44,97	50,41	153,95	165,07	242,70	288,75	610,42	28
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,40	0,00	0,00	0,00	0,00	0,00	2381
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,71	0,00	13,12	48,83	2060
Testis	0,00	0,00	0,00	11,79	0,00	0,00	0,00	0,00	0,00	8,73	0,00	0,00	9,06	0,00	0,00	0,00	0,00	677
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,73	0,00	0,00	0,00	0,00	0,00	13,12	0,00	2291
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,49	0,00	9,06	9,71	0,00	0,00	0,00	762

## Frequency of Cancer by Age Group

ALL FEMALES																		
Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	2330	5	3	5	8	12	36	81	163	198	248	245	260	283	247	248	150	138
All sites but C44	2003	5	3	5	8	9	34	74	149	173	218	216	222	240	209	213	118	107
Anus	21	0	0	0	0	0	0	1	3	4	3	2	3	3	0	0	2	0
BCC	20	0	0	0	0	0	0	1	2	0	2	1	1	2	3	1	3	4
Bladder	14	0	0	0	0	0	0	0	0	3	1	2	0	2	3	0	1	2
Bone	5	0	0	0	1	1	1	0	1	0	1	0	0	0	0	0	0	0
Brain, CNS	30	0	1	0	0	0	0	1	2	4	2	5	3	3	4	2	1	2
Breast	650	0	0	0	1	3	6	15	41	54	59	69	86	83	79	71	45	38
Burkitt lymphoma	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Cervix	363	0	0	0	0	0	6	22	45	43	68	45	46	31	24	22	2	9
Colorectal	129	0	0	1	1	2	0	2	6	8	6	11	10	23	17	15	11	16
Connective tissue	11	1	0	0	0	0	0	1	0	2	2	1	1	0	1	0	1	1
Endocrine	10	1	0	0	1	0	2	0	1	1	0	1	1	0	1	1	0	0
Eye	3	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0
Gum	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
Haematology other	35	0	0	0	0	1	1	1	3	5	2	1	1	4	3	7	3	3
Hodgkin lymphoma	10	0	0	1	0	0	2	2	1	0	1	0	3	0	0	0	0	0
Ill defined	15	0	1	0	0	0	1	2	2	2	0	0	1	2	1	1	2	0
Kaposi Sarcoma	16	0	0	0	0	0	2	3	5	1	3	1	0	1	0	0	0	0
Kidney	9	0	1	0	0	0	0	0	0	1	1	1	1	0	1	1	1	1
Larynx	4	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	1	0
Leukaemia	7	0	0	2	0	0	0	0	0	0	0	0	1	1	1	0	0	2
Lip	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0

Liver & Bile duct	23	0	0	0	0	0	0	0	3	4	2	5	1	4	1	1	0	2
Lung	51	0	0	0	0	0	1	3	0	0	2	4	4	7	7	14	4	5
Melanoma	15	0	0	0	0	2	0	0	1	0	1	1	0	2	0	5	2	1
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
Mouth	12	0	0	0	0	0	0	0	0	0	1	1	2	1	4	3	0	0
Myeloma	7	0	0	0	0	0	0	0	0	1	0	1	1	1	1	1	1	0
Naso-Oropharynx	23	0	0	1	0	0	3	4	2	0	2	1	1	2	1	2	2	2
Non Hodgkin lymphoma	25	0	0	0	1	0	1	1	3	3	7	2	0	1	3	1	2	0
Oesophagus	45	0	0	0	0	0	0	0	1	0	1	6	6	7	9	7	5	3
Other specified	21	0	0	0	0	0	0	0	1	1	3	3	5	3	0	2	1	2
Ovary	57	0	0	0	2	0	1	4	2	4	5	9	8	5	6	9	1	1
Pancreas	19	0	0	0	0	0	0	0	0	0	1	3	1	2	3	2	5	2
Placenta	2	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
Primary site unknown	38	2	0	0	0	0	2	0	2	0	4	5	6	3	4	1	5	4
Salivary gland	7	0	0	0	0	0	1	1	3	0	1	0	0	1	0	0	0	0
Squamous cell carcinoma of skin	355	0	0	0	1	3	4	6	15	26	31	38	42	47	42	41	30	29
Small intestine	4	0	0	0	0	0	0	0	0	1	0	1	0	0	0	2	0	0
Stomach	23	0	0	0	0	0	1	0	1	1	1	3	2	5	4	4	1	0
Thyroid	27	0	0	0	0	0	1	4	3	3	5	4	2	1	2	2	0	0
Tongue	10	0	0	0	0	0	0	0	2	0	1	0	1	3	0	2	1	0
Uterus	110	0	0	0	0	0	0	1	0	2	8	4	11	25	19	21	14	5
Vagina	17	0	0	0	0	0	0	1	0	1	0	3	2	3	2	3	1	1
Vulva	81	0	0	0	0	0	0	3	10	21	19	11	6	3	1	3	2	2

ASIAN FEMALE																		
Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	652	0	0	1	1	3	5	13	26	41	56	66	86	88	88	92	53	33
All sites but C44	541	0	0	1	1	2	4	12	24	32	49	55	72	65	71	82	46	25
Anus	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
Bladder	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1
Brain, CNS	8	0	0	0	0	0	0	0	1	1	0	0	1	1	3	0	1	0
Breast	245	0	0	0	0	1	2	3	10	17	18	28	40	27	34	35	20	10
Cervix	29	0	0	0	0	0	0	0	3	4	5	2	5	4	2	3	0	1
Colorectal	55	0	0	1	0	1	0	1	1	3	2	4	4	10	7	8	6	7
Connective tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Endocrine	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
Gum	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Haematology other	10	0	0	0	0	0	0	0	1	1	0	0	0	1	1	4	2	0
Hodgkin lymphoma	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
Ill defined	4	0	0	0	0	0	0	1	1	0	0	0	0	0	1	1	0	0
Kidney	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Liver & Bile duct	4	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0	0
Lung	18	0	0	0	0	0	0	2	0	0	1	0	3	2	2	5	3	0
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
Mouth	7	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2	0	0
Myeloma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Naso-Oropharynx	4	0	0	0	0	0	0	0	1	0	1	1	0	1	0	0	0	0
Non Hodgkin lymphoma	7	0	0	0	0	0	0	0	0	0	4	0	0	1	2	0	0	0
Oesophagus	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0
Other specified	8	0	0	0	0	0	0	0	0	0	1	3	2	1	0	0	0	1
Ovary	22	0	0	0	1	0	0	3	1	2	4	1	4	1	2	3	0	0

Pancreas	6	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	2	0
Placenta	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Primary site unknown	10	0	0	0	0	0	0	0	0	0	1	2	2	1	2	0	1	1
Salivary gland	3	0	0	0	0	0	0	0	2	0	0	0	0	1	0	0	0	0
Squamous cell carcinoma of skin	124	0	0	0	0	1	3	1	2	10	10	14	15	24	19	10	7	8
Small intestine	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Stomach	8	0	0	0	0	0	0	0	1	0	1	1	1	1	1	1	1	0
Thyroid	13	0	0	0	0	0	0	1	2	2	3	2	1	1	0	1	0	0
Tongue	5	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	1	0
Uterus	35	0	0	0	0	0	0	0	0	1	3	1	4	5	5	11	4	1
Vagina	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0
Vulva	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0

BLACK FEMALE

Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	1166	5	3	4	7	8	29	62	117	143	162	128	127	122	87	76	41	45
All sites but C44	1043	5	3	4	7	6	28	57	106	129	144	117	107	113	81	64	34	38
Anus	15	0	0	0	0	0	0	1	3	4	3	0	2	0	0	0	2	0
BCC	7	0	0	0	0	0	0	1	2	0	2	0	1	0	0	0	1	0
Bladder	10	0	0	0	0	0	0	0	0	3	1	2	0	2	1	0	0	1
Bone	5	0	0	0	1	1	1	0	1	0	1	0	0	0	0	0	0	0
Brain, CNS	13	0	1	0	0	0	0	1	1	3	0	2	1	1	0	2	0	1
Breast	229	0	0	0	1	2	4	12	20	28	29	21	30	27	22	12	11	10
Burkitt lymphoma	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Cervix	320	0	0	0	0	0	6	19	42	39	62	43	36	25	22	17	2	7
Colorectal	34	0	0	0	1	1	0	1	4	3	2	3	3	7	3	2	0	4
Connective tissue	9	1	0	0	0	0	0	1	0	2	2	0	1	0	1	0	1	0
Endocrine	8	1	0	0	1	0	2	0	1	1	0	0	1	0	0	1	0	0
Eye	3	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0
Haematology other	17	0	0	0	0	1	1	1	2	4	2	1	1	3	1	0	0	0
Hodgkin lymphoma	8	0	0	1	0	0	2	2	1	0	1	0	1	0	0	0	0	0
Ill defined	10	0	1	0	0	0	1	1	1	2	0	0	1	2	0	0	1	0
Kaposi Sarcoma	16	0	0	0	0	0	2	3	5	1	3	1	0	1	0	0	0	0
Kidney	3	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0
Larynx	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Leukaemia	3	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Lip	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Liver & Bile duct	17	0	0	0	0	0	0	0	3	4	1	4	1	2	1	0	0	1
Lung	17	0	0	0	0	0	0	1	0	0	1	3	1	4	2	3	0	2
Melanoma	9	0	0	0	0	1	0	0	1	0	1	1	0	0	0	2	2	1
Mouth	4	0	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	0

Myeloma	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0
Naso-Oropharynx	14	0	0	1	0	0	3	4	1	0	1	0	1	1	0	1	0	1
Non Hodgkin lymphoma	12	0	0	0	1	0	1	1	1	3	2	1	0	0	0	0	2	0
Oesophagus	39	0	0	0	0	0	0	0	1	0	1	6	5	7	6	6	4	3
Other specified	7	0	0	0	0	0	0	0	1	1	1	0	1	2	0	1	0	0
Ovary	24	0	0	0	1	0	1	1	1	2	0	7	3	4	2	1	0	1
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Placenta	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Primary site unknown	16	2	0	0	0	0	2	0	1	0	3	3	2	1	1	0	1	0
Salivary gland	3	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0
Squamous cell carcinoma of skin	128	0	0	0	1	2	1	4	11	14	16	14	20	9	9	13	7	7
Small intestine	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0
Stomach	10	0	0	0	0	0	1	0	0	1	0	2	0	3	3	0	0	0
Thyroid	6	0	0	0	0	0	0	2	0	1	1	0	1	0	1	0	0	0
Tongue	2	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0
Uterus	50	0	0	0	0	0	0	0	0	0	3	1	5	15	8	9	6	3
Vagina	11	0	0	0	0	0	0	1	0	1	0	2	2	2	1	1	0	1
Vulva	77	0	0	0	0	0	0	3	10	21	19	11	5	3	1	2	1	1

COLOURED FEMALES																		
Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	56	0	0	0	0	0	1	1	4	3	3	5	5	12	8	7	2	5
All sites but C44	50	0	0	0	0	0	1	1	4	3	3	4	5	10	8	6	2	3
Anus	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
BCC	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Breast	23	0	0	0	0	0	0	0	3	2	3	2	1	4	4	3	0	1
Cervix	6	0	0	0	0	0	0	1	0	0	0	0	1	1	0	2	0	1
Colorectal	6	0	0	0	0	0	0	0	0	1	0	0	1	1	3	0	0	0
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Lung	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Skin other	6	0	0	0	0	0	0	0	0	0	0	2	0	2	0	1	0	1
Stomach	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Thyroid	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Tongue	2	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0
Uterus	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0
Vulva	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0

WHITE FEMALES																		
Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	456	0	0	0	0	1	1	5	16	11	27	46	42	61	64	73	54	55
All sites but C44	369	0	0	0	0	1	1	4	15	9	22	40	38	52	49	61	36	41
Anus	3	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0
BCC	11	0	0	0	0	0	0	0	0	0	0	1	0	1	3	1	2	3
Brain, CNS	9	0	0	0	0	0	0	0	0	0	2	3	1	1	1	0	0	1
Breast	153	0	0	0	0	0	0	0	8	7	9	18	15	25	19	21	14	17
Cervix	8	0	0	0	0	0	0	2	0	0	1	0	4	1	0	0	0	0
Colorectal	34	0	0	0	0	0	0	0	1	1	2	4	2	5	4	5	5	5
Connective tissue	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Gum	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Haematology other	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1	2
Ill defined	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Kidney	5	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	1
Larynx	3	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0
Leukaemia	3	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0
Liver & Bile duct	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Lung	15	0	0	0	0	0	0	0	0	0	0	1	0	1	3	6	1	3
Melanoma	6	0	0	0	0	1	0	0	0	0	0	0	0	2	0	3	0	0
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Myeloma	3	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0
Naso-Oropharynx	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1
Non Hodgkin lymphoma	6	0	0	0	0	0	0	0	2	0	1	1	0	0	1	1	0	0
Oesophagus	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0
Other specified	6	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	1	1
Ovary	11	0	0	0	0	0	0	0	0	0	1	1	1	0	2	5	1	0
Pancreas	11	0	0	0	0	0	0	0	0	0	1	1	0	1	3	1	2	2

Primary site unknown	12	0	0	0	0	0	0	0	1	0	0	0	2	1	1	1	3	3
Salivary gland	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma of skin	97	0	0	0	0	0	0	1	2	2	5	8	7	12	14	17	16	13
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Stomach	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	0	0
Thyroid	7	0	0	0	0	0	1	1	1	0	1	1	0	0	1	1	0	0
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Uterus	21	0	0	0	0	0	0	1	0	1	2	2	2	4	5	0	3	1
Vagina	3	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0
Vulva	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

ALL MALES																		
Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	1593	4	5	3	12	12	10	25	36	58	91	123	189	226	249	207	201	142
All sites but C44	1289	4	5	3	11	12	7	23	33	45	76	105	151	186	206	167	153	102
Anus	6	0	0	0	0	0	0	0	1	1	0	1	2	0	1	0	0	0
BCC	31	0	0	0	0	0	0	0	0	0	1	0	2	4	5	6	5	8
Bladder	43	0	0	0	0	0	0	0	0	2	2	7	1	3	4	11	8	5
Bone	14	0	0	0	0	1	0	0	0	0	0	0	0	4	4	0	2	3
Brain, CNS	23	0	1	1	1	1	1	1	2	3	1	3	2	1	1	1	1	2
Breast	10	0	0	0	0	1	0	0	1	0	1	1	0	2	1	1	2	0
Burkitt lymphoma	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Colorectal	144	0	0	0	0	0	0	0	5	7	14	14	20	15	21	20	19	9
Connective tissue	14	1	1	0	0	0	1	0	1	2	0	1	1	1	1	2	0	2
Endocrine	5	0	0	0	1	0	0	1	0	0	0	0	0	1	1	0	1	0
Eye	8	1	0	0	0	0	0	0	0	0	1	4	0	0	0	1	0	1
Haematology other	44	0	0	0	1	1	1	2	2	3	4	4	3	2	10	3	4	4
Hodgkin lymphoma	6	0	0	0	1	0	0	0	0	0	0	1	0	2	1	0	0	1
Ill defined	9	0	0	1	0	1	0	2	0	0	1	1	0	1	1	0	0	1
Kaposi Sarcoma	21	0	0	0	0	0	0	6	5	3	0	1	4	1	0	0	1	0
Kidney	19	2	0	1	0	0	0	0	0	0	2	0	1	5	2	4	2	0
Larynx	34	0	0	0	0	0	0	0	1	1	2	3	4	11	4	0	3	5
Leukaemia	8	0	0	0	0	0	0	2	0	0	0	0	1	1	0	3	0	1
Lip	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0
Liver & Bile duct	22	0	0	0	0	1	0	1	2	2	1	3	2	1	2	4	2	1
Lung	116	0	0	0	0	0	0	1	2	2	9	9	15	23	20	16	11	8
Melanoma	14	0	0	0	0	0	0	0	0	0	1	1	4	4	2	0	0	2
Mesothelioma	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0
Mouth	17	0	1	0	0	0	0	1	1	0	0	2	2	5	3	0	1	1

Myeloma	9	0	0	0	0	0	0	0	0	0	3	1	0	3	1	0	1	0
Naso-Oropharynx	25	0	0	0	1	0	1	2	3	1	2	3	4	1	5	1	1	0
Non Hodgkin lymphoma	29	0	0	0	1	3	0	1	1	2	1	5	3	3	3	2	2	2
Oesophagus	31	0	0	0	0	0	0	0	0	1	0	1	9	11	2	3	2	2
Other specified	23	0	0	0	0	0	1	0	1	1	1	2	4	3	3	3	4	0
Pancreas	29	0	0	0	0	0	0	0	0	1	7	0	3	8	4	2	2	2
Penis	16	0	0	0	0	0	0	0	1	2	3	5	3	1	0	0	0	1
Primary site unknown	40	0	0	0	1	1	0	0	0	1	5	5	4	5	4	3	4	7
Prostate	411	0	0	0	0	0	1	0	0	0	8	20	49	60	90	76	71	36
Salivary gland	6	0	0	0	0	0	0	1	0	0	0	0	0	0	4	0	1	0
Squamous cell carcinoma of skin	276	0	0	0	1	0	3	0	5	13	14	20	36	37	38	35	42	32
Small intestine	4	0	0	0	0	0	0	0	0	0	0	0	3	0	0	1	0	0
Stomach	40	0	0	0	0	0	0	0	2	5	0	3	4	2	8	6	4	6
Testis	17	0	1	0	4	2	1	4	0	2	1	0	0	1	0	0	1	0
Thyroid	8	0	0	0	0	0	0	0	0	3	1	0	1	1	0	1	1	0
Tongue	14	0	0	0	0	0	0	0	0	0	3	2	2	3	2	1	1	0

ASIAN MALES

Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	427	0	0	1	1	3	2	5	7	15	25	39	50	75	55	54	60	35
All sites but C44	351	0	0	1	1	3	2	5	5	14	20	33	42	60	47	45	43	30
Bladder	18	0	0	0	0	0	0	0	0	1	1	4	0	2	3	3	2	2
Bone	7	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	1	2
Brain, CNS	7	0	0	1	1	0	0	0	1	1	0	1	1	1	0	0	0	0
Breast	4	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	0
Colorectal	60	0	0	0	0	0	0	0	1	3	7	8	10	6	7	9	6	3
Connective tissue	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1
Endocrine	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
Haematology other	15	0	0	0	0	0	1	0	1	0	1	2	2	1	2	1	1	3
Hodgkin lymphoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Kidney	9	0	0	0	0	0	0	0	0	0	2	0	0	3	1	2	1	0
Larynx	11	0	0	0	0	0	0	0	0	0	0	0	3	3	3	0	2	0
Leukaemia	4	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	0	0
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Liver & Bile duct	5	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	1	1
Lung	25	0	0	0	0	0	0	0	0	0	0	3	2	8	6	2	2	2
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0
Myeloma	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
Naso-Oropharynx	3	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0
Non Hodgkin lymphoma	9	0	0	0	0	1	0	0	1	0	0	1	1	1	2	0	2	0
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Other specified	5	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	2	0
Pancreas	8	0	0	0	0	0	0	0	0	0	2	0	2	3	1	0	0	0

Penis	4	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	1
Primary site unknown	12	0	0	0	0	0	0	0	0	0	1	3	2	1	2	1	1	1
Prostate	87	0	0	0	0	0	0	0	0	0	2	7	11	14	9	16	17	11
Salivary gland	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Squamous cell carcinoma of skin	79	0	0	0	0	0	0	0	3	1	5	7	8	16	8	9	17	5
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Stomach	21	0	0	0	0	0	0	0	0	3	0	1	3	2	3	4	3	2
Testis	9	0	0	0	0	2	1	4	0	2	0	0	0	0	0	0	0	0
Thyroid	3	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0
Tongue	5	0	0	0	0	0	0	0	0	0	1	0	2	1	0	1	0	0

BLACK MALES

Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	597	4	5	2	9	7	8	18	25	35	58	68	97	79	97	46	26	13
All sites but C44	521	4	5	2	8	7	5	16	24	27	50	61	75	75	84	44	24	10
Anus	6	0	0	0	0	0	0	0	1	1	0	1	2	0	1	0	0	0
BCC	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Bladder	9	0	0	0	0	0	0	0	0	1	1	2	0	0	1	2	2	0
Bone	3	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	0
Brain, CNS	8	0	1	0	0	1	1	0	0	2	0	1	1	0	1	0	0	0
Breast	3	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0
Burkitt lymphoma	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Colorectal	42	0	0	0	0	0	0	0	4	3	6	5	5	4	8	3	3	1
Connective tissue	5	1	1	0	0	0	1	0	1	0	0	0	0	0	1	0	0	0
Endocrine	3	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0
Eye	6	1	0	0	0	0	0	0	0	0	1	4	0	0	0	0	0	0
Haematology other	16	0	0	0	1	0	0	2	1	3	3	2	1	1	0	1	1	0
Hodgkin lymphoma	3	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	0	0
Ill defined	6	0	0	1	0	1	0	2	0	0	1	1	0	0	0	0	0	0
Kaposi Sarcoma	21	0	0	0	0	0	0	6	5	3	0	1	4	1	0	0	1	0
Kidney	5	2	0	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0
Larynx	16	0	0	0	0	0	0	0	1	1	2	3	1	6	0	0	0	2
Lip	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Liver & Bile duct	12	0	0	0	0	1	0	1	2	1	1	2	2	0	1	1	0	0
Lung	53	0	0	0	0	0	0	1	2	2	9	6	9	12	5	6	0	1
Melanoma	6	0	0	0	0	0	0	0	0	0	1	1	2	2	0	0	0	0
Mesothelioma	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Mouth	11	0	1	0	0	0	0	1	1	0	0	2	1	4	1	0	0	0

Myeloma	4	0	0	0	0	0	0	0	0	0	2	1	0	1	0	0	0	0
Naso-Oropharynx	17	0	0	0	1	0	1	2	3	1	0	2	4	0	2	0	1	0
Non Hodgkin lymphoma	12	0	0	0	1	1	0	1	0	1	1	4	2	1	0	0	0	0
Oesophagus	24	0	0	0	0	0	0	0	0	1	0	1	9	9	1	2	0	1
Other specified	11	0	0	0	0	0	1	0	1	1	1	2	2	1	1	1	0	0
Pancreas	12	0	0	0	0	0	0	0	0	1	5	0	1	3	2	0	0	0
Penis	12	0	0	0	0	0	0	0	1	2	2	4	3	0	0	0	0	0
Primary site unknown	16	0	0	0	1	1	0	0	0	1	4	1	2	3	2	0	1	0
Prostate	151	0	0	0	0	0	1	0	0	0	6	11	20	22	50	26	11	4
Salivary gland	2	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0
Squamous cell carcinoma of skin	72	0	0	0	1	0	3	0	1	8	7	7	22	4	13	2	2	2
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
Stomach	12	0	0	0	0	0	0	0	1	2	0	2	1	0	4	1	0	1
Testis	4	0	1	0	2	0	0	0	0	0	0	0	0	0	0	0	1	0
Thyroid	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0
Tongue	5	0	0	0	0	0	0	0	0	0	2	1	0	1	1	0	0	0

**COLOURED MALES**

Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	30	0	0	0	1	1	0	0	1	0	1	1	2	3	3	10	2	5
All sites but C44	26	0	0	0	1	1	0	0	1	0	1	1	2	3	3	7	1	5
BCC	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Bone	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Brain, CNS	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Colorectal	2	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
Connective tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Lung	6	0	0	0	0	0	0	0	0	0	0	0	1	1	2	2	0	0
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Non Hodgkin lymphoma	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Primary site unknown	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0
Prostate	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	1
Squamous cell carcinoma of skin	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
Stomach	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1
Testis	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0

WHITE MALES																		
Site	All Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	539	0	0	0	1	1	0	2	3	8	7	15	40	69	94	97	113	89
All sites but C44	391	0	0	0	1	1	0	2	3	4	5	10	32	48	72	71	85	57
BCC	28	0	0	0	0	0	0	0	0	0	1	0	2	4	5	4	5	7
Bladder	16	0	0	0	0	0	0	0	0	0	0	1	1	1	0	6	4	3
Bone	3	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0
Brain, CNS	7	0	0	0	0	0	0	1	1	0	1	0	0	0	0	1	1	2
Breast	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0
Colorectal	40	0	0	0	0	0	0	0	0	1	0	1	5	5	5	8	10	5
Connective tissue	5	0	0	0	0	0	0	0	0	2	0	1	0	0	0	2	0	0
Eye	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Haematology other	13	0	0	0	0	1	0	0	0	0	0	0	0	0	8	1	2	1
Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Ill defined	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1
Kidney	5	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	0	0
Larynx	7	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	3
Leukaemia	4	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	1
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Liver & Bile duct	5	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	1	0
Lung	32	0	0	0	0	0	0	0	0	0	0	0	3	2	7	6	9	5
Melanoma	8	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0	0	2
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Mouth	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Myeloma	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0
Naso-Oropharynx	5	0	0	0	0	0	0	0	0	0	1	1	0	0	3	0	0	0

Non Hodgkin lymphoma	7	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	2	0	2
Oesophagus	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1
Other specified	7	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	2	0
Pancreas	9	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	2	2	2
Primary site unknown	9	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	6
Prostate	169	0	0	0	0	0	0	0	0	0	0	0	2	17	24	31	32	43	20
Salivary gland	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0
Squamous cell carcinoma of skin	123	0	0	0	0	0	0	0	0	1	4	2	6	6	17	17	23	22	25
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Stomach	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2
Testis	3	0	0	0	1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
Thyroid	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
Tongue	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0